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Abstract: 
Sepsis is an infection, usually bacterial, of normally sterile parts of the body and leads 
to systemic illness and a panoply of non-selective inflammatory responses that are non-
specific. Preterm neonates (infants born <37 weeks gestation) are particularly affected 
by sepsis with a prevalence up to 62%, particularly LOS acquired after 72 hours of life, 
caused from micro-organisms acquired either perinatally or postnatally usually as a 
consequence of nosocomial transmission. Increased antibiotic resistant bacteria 
prevalence has also made treating preterm sepsis more challenging thus new treatments 
are required to overcome the antibiotic resistance. Synergy between AMPs/antibiotics 
has been documented before but very few studies at present test various combinations 
of AMPs/antibiotics in human whole blood. This study set out to determine the 
optimum combination of AMPs, rBPI21, LF, IDR-1018 and LL-37, and antibiotics, 
Vancomycin and Ceftriaxone, to kill common sensitive and resistant preterm infant 
clinical isolate sepsis causing bacteria (S. aureus, MRSA, E. coli and ESBL E. coli), 
inoculated into donated healthy adult whole blood. This study showed that the 
Vancomycin and IDR-1018 combination was the only combination that had a 
significantly increased inhibitory effect, against E. coli despite the Vancomycin 
resistance of E. coli. This study also found that only IDR-1018 had any inhibitory 
activity against three of the four bacteria used (E. coli, MRSA and ESBL E. coli). We 
found that the endogenous levels of AMPs and immune cells in donor blood had no 
effect on the bacteria used in the study at the doses tested. To conclude, this study found 
a combination of AMPs/antibiotic that can potentially improve sepsis treatment in 
preterms. But more work is needed to ensure that this combination is a viable new 
treatment for preterm infant sepsis. 
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1 Chapter 1 Introduction/Literature Review 
1.1 Sepsis Definition: 
Sepsis is an infection, usually bacterial, of normally sterile parts of the body and leads 
to systemic illness and a panoply of non-selective inflammatory responses that are non-
specific (1). Common sites include the respiratory tract (the most common site), skin, 
urinary tract, the peritoneal cavity and other places, the origin can be from indwelling 
catheters or any devices put into the patient, trauma can also allow bacterial entry such 
as burns and major surgery (2, 3). The respiratory tract, is associated with the highest 
sepsis mortality, in men and alcoholics (3). Women are more prone to urogenital site 
infection (3). Other common sites are endocarditis, device related, Central Nervous 
System, soft tissues, abdomen and skin (3). The presence of infection differentiates 
sepsis from identical clinical syndromes that can occur from several non-microbial 
conditions, pancreatitis being the archetype (1). Sepsis is also a multi-step process 
involving an uncontrolled inflammatory response by the patient’s cells, the result leads 
to multi-organ failure and death (4). Finally, sepsis can be seen as the final common 
pathway of many different infectious pathways such as parasitic, viral, fungal and 
bacterial infections in high risk groups (5).  
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) 
states that sepsis should be defined as “life-threatening organ dysfunction caused by a 
dysregulated host response to infection. For clinical operationalization, organ 
dysfunction can be represented by an increase in the Sequential [Sepsis-related] Organ 
Failure Assessment (SOFA) score of 2 points or more, which is associated with an in-
hospital mortality greater than 10%. Septic shock should be defined as a subset of sepsis 
in which particularly profound circulatory, cellular, and metabolic abnormalities are 
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associated with a greater risk of mortality than with sepsis alone” as seen in Table 1 
from (6).   
Table 1. SOFA scores representing increasing mortality probability of the patient (6). 
 Score     
































































1. The dose of catecholamine are given for at least an hour as µg/kg/min. 
2. The range of the Glasgow Coma Score are 3-15; a higher score means a better neurological function 
1.2 Sepsis Epidemiology and Pathophysiology: 
1.2.1 The Pathophysiology of Sepsis: 
When bacteria replicate within a patient they release antigens and other active factors, 
such as endotoxins from the Gram-negative (GN) bacteria and exotoxins from the 
Gram-positive (GP) bacteria, activating an immune response to clear the invading 
bacteria (2). The activated immune system releases cytokines including, Tumor 
Necrosis Factor (TNF)-α, IL-1β, IL-2, IL-6, IL-8, and Interferon IFN-γ, which further 
activate neutrophils, monocytes, and endothelial cells (2, 7). As well as the cellular and 
cytokine involvement in bacterial sepsis, there is also involvement from the 
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neuroendocrine, complement, coagulation and fibrinolytic systems (2). Homeostasis 
maintenance is attempted by the release of anti-inflammatory cytokines (TGF-β, 
Interleukin (IL)-4, IL-10, and IL-13) and the cytokine inhibitors (IL-1 receptor 
antagonist) to quell the pro-inflammatory cytokine response (2).   
A hyperactive pro-inflammatory, cytokine storm, response to bacterial sepsis causes 
physiological changes such as damage to the tissues, organs and other systems in an 
attempt to clear the bacteria (7-9). However this level of inflammatory response to 
bacterial sepsis may actually be the appropriate response to the high level of bacterial 
infection, but the attempt to compensate for the collateral damage from the 
inflammatory response is too great (9).  
Immunosuppression, is also observed in patients with sepsis in the Intensive Care Unit 
(8). There is a lack both TNF and IL-6 production in response to the bacterial toxins, 
but the production of IL-10 in bacterial sepsis patients is not suppressed (8). This means 
that while the pro-inflammatory response is potentially supressed, the anti-inflammatory 
response continues to work (8). However, it became apparent that prolonged 
immunoparalysis follows, in trying to compensate for, the hyperactive pro-
inflammatory response (7). Thus, sepsis occurs in two variable stages that the patient 
cycles through (7).   
T-lymphocytes in sepsis patients are also affected, being unable to proliferate in the 
presence of the mitogen stimulation and failing to produce IL-2 or IL-12 (8). B7 and 
CD28 molecules engaging on Antigen Presenting Cells (APCs) are essential 
requirements for pro-survival T-lymphocyte factors, B-cell Lymphoma-extra large and 
IL-2, expression (7). Decreased B7-CD80 and B7-2/CD86 expression on APCs from 
septic patients lung or spleen, potentially limited T-lymphocyte ability to receive co-
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stimulation (7). T-lymphocytes become anergic or undergo a death by neglect process 
without B7/CD28 co-stimulation (7). 
T-lymphocytes also potentially undergo apoptosis when APCs stimulate the T-
lymphocytes with altered signals (9). The increased expression of Cytotoxic T-
lymphocyte-Associated Antigen-4/CD152 (a T-cell co-stimulatory inhibitory ligand), 
Programmed Death receptor (PD)-1 on T-lymphocytes/PD-L1/2 (ligands on APCs), and 
B- and T-lymphocyte attenuator also induces anergy and the apoptosis process (7, 9). 
Pro-inflammatory cytokines and chemokines activated by the large early release of 
TNF-α in sepsis, working in conjunction with TNF-α also cause T-lymphocytes 
apoptosis (7). 
Another reason the T-lymphocytes have a decreased activity in septic patients is 
because there is an observed increase in the CD4+CD25+ T-regulatory cells (10). These 
cells express PD-L, Cytotoxic T-lymphocyte-Associated Antigen-4 and TNF receptor 
ligand family members such as Fas-Ligand (CD95L) (7). When the expression of the 
transcription factor, Foxp3, necessary for T-regulatory cell function is silenced in 
splenocytes in septic mice, the T-cells proliferative response is restored (10). 
Complement factor C5a binding to its receptor C5aR on thymocytes in mouse sepsis 
models causes apoptosis (7).  
Neutrophils, in bacterial sepsis can become dysfunctional by either releasing greater 
than normal levels or continuously releasing normal levels of toxic products, via the 
respiratory burst, (Reactive Oxygen Intermediates (ROI)/Reactive Oxygen Species 
(ROS) and Reactive Nitrogen Species such as hydroxyl radicals, superoxide anion, 
Nitric Oxide (NO), hydrogen peroxide and peroxynitrate) causing damage to nearby 
cells (8, 9, 11). They can also lose their ability to clear invading pathogens by 
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phagocytosis, this shows heterogeneity in response by patients with some patients 
having an overactive response to sepsis and others having a blunted one (8, 9, 11).  
Apoptosis, from bacterial sepsis has been found to occur in cell types such as muscle 
cells, neurons, endothelial cells, the most pronounced apoptosis has been in the 
lymphocytes and the gastrointestinal epithelial cells (9). The tissue sites of this 
accelerated apoptosis are the spleen and thymus and other lymphoid organs such as the 
large intestine while rare in the non-lymphoid tissues (9). Sepsis pathogenesis is 
promoted by, the delayed removal of apoptotic cells that should be removed once their 
function is done, such as the neutrophils, and the increased removal of the lymphocytes 
before they have a chance to attack the sepsis causing bacteria (8, 9). Neutrophils 
persisting longer than they should and continuing to release their soluble toxic products, 
could add to organ damage and mortality from bacterial sepsis (9). In septic patients, 
through sepsis induced accelerated apoptosis, the degree of loss of the splenic B-cell 
and CD4+ T-cell subset of lymphocytes, Dendritic Cells (DCs) (both interdigitating and 
follicular) and the circulating B-cell and CD4+ T-cell subset of lymphocytes, and also 
CD8+ T-cells and Natural Killer (NK) cells and the sepsis symptom severity and 
outcome in septic patients is closely correlated (9).  
1.2.2 Epidemiology of Sepsis in Different Age Groups: 
The World Health Organisation does not list sepsis as a causes of death, however it does 
list the leading cause of sepsis, lower respiratory tract infection, as a leading cause of 
death (12). Bacterial sepsis affects people in all age groups, the proportions can be seen 
in Table 2, but the most affected are preterms (particularly extremely young preterms) 
and the very old meaning that sepsis shows a bimodal age distribution (12, 13). Factors 
affecting sepsis incidence are as follows: men have shown a higher association of sepsis 
infection than women, but women five years older have similar age-adjusted incidences, 
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racial disparity between African and Caucasian with Africans having a two-fold 
increase in severe sepsis incidences compared to Caucasians most occurring in the 35-
44 years age group, co-morbid conditions are another factor that may increase sepsis 
risk, as discussed later, and finally geography and season with the south-eastern states 
of the United States showing higher sepsis mortality incidence and winter showing an 
increased respiratory infection, Streptococcal and Pneumococcal sepsis incidence 
diagnoses but no other sepsis causes (12).  
Table 2. Proportion of age groups that get sepsis 
Age Group Sepsis Prevalence % in the Age 
Groups 
Reference 
Preterm infants (Neonates) (22 weeks, 23 
weeks, 24 weeks, 25 weeks, 26 weeks, 27 
weeks and 28 weeks)1* 
6-58%, 4-62%, 4-5%, 2-46%, 2-
35%, 2-27% and 1-20% 
(14, 15) 
Children (0-2 months, 3-23 months, 2-4 years, 
5-12 years, 13-17 years) 
18.8%, 8.5%, 4.9%, 6.4% and 5.1%   (16) 
Adults (18 years and up) 6-30% (17) 
Elderly Adults ≥65 years. 60% (18, 19) 
1. ~60% of sepsis cases for the most immature infants. *The focus of this study. 
1.2.3 Neonate and Preterm Birth Definition:  
A neonate is an infant in the first 28 days of life, particularly the term neonate is used 
during the first week of life (20). Preterm birth is defined as any child birth occurring 
before the complete 37 week gestation, 40 weeks is the normal term birth for an infant 
(21, 22). Preterms can be further divided into different sub-groups depending on 
Gestational Age (GA) of the infant; <28 weeks gestation defines an extremely preterm 
infant, between 28 and <32 weeks are very preterm infants, and finally moderate 
preterms defined as between 32 and <37 weeks (22). The lowest gestation humans can 
be born and still live is 22 weeks, and infants born earlier than this unfortunately cannot 
survive even if they receive optimum medical care (23). Thus, preterm neonates are 
infants born earlier than 37 weeks complete gestation and is in the first 28 days of life. 
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1.2.4 Sepsis Associated with Preterm Birth: 
Sepsis is an important and common cause of both mortality and morbidity in preterm 
and term infants (24) with an incidence rate that can vary between one and eight 
affected neonates per 1000 live births (25, 26). >90% of neonatal deaths are in 
developing countries while <10% of neonatal deaths are in developed countries (22, 
27). Sepsis is dependent on both Birth Weight (BW) of the baby and GA, with extreme 
preterms, <28 weeks of gestation, being the significant minority affected by infection, 
nosocomial infection in particular (26). While in developed countries extremely preterm 
birth is only around 1.0% of all births, these preterms disproportionately contribute to 
neonatal mortality and morbidity at around 50% with the leading cause of the adverse 
outcome being infection related complications (26).  
Neonatal sepsis can be divided into three categories pertaining to its onset (25); Early 
Onset Sepsis (EOS) acquired within the first 72 hours of life, usually from micro-
organisms from the mother’s genital tract (25). Next is Late Onset Sepsis (LOS) usually 
acquired after 72 hours of life, caused from micro-organisms acquired either perinatally 
or postnatally usually as a consequence of nosocomial transmission (25). Finally, Very 
Late Onset Sepsis (VLOS), usually diagnosed in Extremely Low Birth Weight infants 
who after several weeks after birth have remained hospitalised (25). Sepsis pathogens in 
neonates have over time changed, vary from place to place and vary between the 
developing and developed worlds (25). The three onsets of sepsis in neonates, EOS, 
LOS and VLOS, all vary from each other in their causative microorganisms, treatment 
for those microorganisms, risk factors and their clinical and laboratory findings (25). 
The most common sepsis category affecting preterms is LOS, preterms with a birth 
weight <750g the cumulative incidence of LOS is 43% (28, 29). Sepsis is a major 
problem in preterms, bacterial sepsis can be caused by both GP and GN bacteria. 
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1.2.5 Common Sepsis Causing Bacteria in Preterm EOS/LOS/VLOS: 
The most common EOS causing bacteria affecting preterms are Group B Streptococcus 
(GBS) also known as S. agalactiae, GBS is also the most important EOS pathogen (25, 
30, 31), Escherichia coli, Haemophilus influenzae, and Listeria monocytogenes in 
developed countries but in developing countries the most common EOS causing 
bacteria is Coagulase Negative Staphylococci (CONS), a heterogeneous group of 
bacteria containing 38 different bacteria including: S. epidermidis, S. haemolyticus, S. 
capitis, S. hominis, S. pettenkoferi, S. simulans, S. warneri and others the next one is S. 
agalactiae (32-34). The most common LOS causing bacteria affecting preterms include 
CONS, S. aureus, E. coli, Klebsiella species, Pseudomonas species, Enterobacter 
species, GBS, Serratia species, Acinetobacter species, and finally anaerobes (25). 
Interestingly, CONS has recently been found to be a common pathogen in both EOS 
and LOS sepsis categories, causing mortality in preterms more so in LOS (25, 34). For 
VLOS causing bacteria, the most common are the Enterococcus species, Klebsiella 
species and CONS (35). The sepsis causing bacteria and fungi found in a study of 151 
preterms can be seen in Table 3. (25). 
Preterm sepsis is caused by broad spectrum antibiotics use, parenteral nutrition and 
prolonged use of invasive procedures, such as indwelling catheters or any devices put 
into the infant (2, 25). CONS is such a problem for preterms because of their impaired 
intestinal colonisation process due to the above reasons, they are at a higher risk of 
pathogenic microflora from intestinal disturbances (25). Preterms losing commensal gut 
microflora causes increased susceptibility to pathogenic gut bacteria colonisation, 
combined with preterms immature skin or the skin being damaged causes S. aureus to 
disseminate from their colonisation site (25).  
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Table 3. The different sepsis causing bacteria and fungi and the distributions in 
EOS/LOS/VLOS (25). 
 
1.2.6 Antibiotic Resistant Sepsis Causing Bacteria on the Rise: 
Lim et al. (36) showed Methicillin-Resistant S. aureus (MRSA) and Extended-Spectrum 
Beta-Lactamase (ESBL) E. coli had a prevalence of 3.2% and 0.6% respectively in 
Very Low Birth Weight infants. Pooja et al. (37) found MRSA and ESBL E. coli have a 
prevalence of 52% and 27.7% respectively in Very Low Birth Weight preterms, 
meaning antibiotic resistant sepsis causing bacteria are showing a high prevalence thus 
making antibiotic treatment more difficult. 
1.3 Preterm Compared to Term/Adult Immune Response to Sepsis Infection: 
1.3.1 Preterm Immune System when Challenged by Sepsis Infection: 
Preterms have a weak innate/adaptive immune system, and deficient interaction of these 
systems (21, 23). Preterms compared to term infants have smaller numbers of both 
monocytes and neutrophils (21). These cells in addition, have impaired pathogen killing 
ability and finally a lower T-cell activation, a lower ability to discover viruses within 
cells and fight bacteria due to lower cytokine production (21). Preterm adaptive 
immunity is immature or not active, compared to adult adaptive immunity. Due to 
requiring time to develop its specificity and memory, that is only finished by early 
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childhood, and deficiencies in the adaptive immune cells abilities. T-cell response in the 
first day of life is enhanced, but after two weeks of birth decreases compared to term 
infants and adults. When challenged by sepsis causing bacteria they require innate 
immunity to try to keep them safe from the infection (21, 23, 38, 39), problem is, innate 
immunity of preterms is too immature to handle an infection like sepsis (21). Neonatal 
murine mice, show defects in their peritoneal myeloid cell populations and have an 
attenuated inflammatory response to sepsis (38). These deficiencies or immaturities, are 
also evident in the innate immunity of preterms with extracellular traps of neutrophils 
being poorly produced, and effector cells of innate immunity showing impaired 
phagocytic ability (23, 38).   
1.3.2 Preterm Immunoglobulins and Other Soluble Molecules Involved in 
Fighting Sepsis Infection: 
Immunoglobulins (Igs) play an important part in infant infection defence, while 
developing its own immune system, particularly maternal IgG that is passively 
transferred to the infant through the placenta after 32 weeks (21, 26). Term infants for 
this reason compared to preterms, have higher maternal IgG (21, 39). Both preterm and 
term infants have an inactive/immature adaptive immune system which limits 
production of other Ig (IgA, IgG and IgE). Both preterm and term infants also have 
reduced class switching of Ig to better fight the infection type being faced (21). The 
reason neonates, especially preterms, have reduced class switching is because they lack 
the co-stimulatory molecules CD40, CD86 and CD40 ligand. Due to this, CD40 cannot 
bind to neonatal naïve B-cells and thus cannot aid in class switching from the common 
IgM neonates produce in a limited degree, compared to adults, to any other Ig (21, 40). 
Maternal IgG levels start dropping off rapidly after the first week of life before infants 
begin to create their own Ig (26). Due to lower maternal IgG levels and a decreased 
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capacity of the complement system, with a low amount of complement protein 3a, 
factor H and I and the C1, C4 classical and factor b alternative pathways in preterms, 
preterm infants also suffer from decreased efficiency of opsonisation and phagocytosis 
making them more susceptible to sepsis infection (21, 23, 26).  
Antimicrobial Peptides (AMPs) are another part of innate immunity, for infants they 
provide not only a first line of defence against infection but may also play a part in 
infant initial colonisation (26). AMP production is also positively correlated with GA 
(21, 26). Preterms have lower AMP levels, for example Bactericidal/Permeability 
Increasing protein (BPI), compared to term infants and adults; term infant BPI is three-
four times less than adults (39). The preterms lower AMP levels effects the Toll-Like 
Receptors (TLR), as AMPs and TLRs work together in an immune response via TLRs 
inducing expression/or release of AMPs once they recognise PAMPs through 
homophilic interaction with the Toll/IL-1 Receptor domain of adaptor proteins results in 
downstream signalling cascade causing activation of transcription factor nuclear factor-
kap-paB which controls an array of inflammatory cytokine genes (41), on the other side 
AMPs can via TLR pathway or TLR relate pathway activation enhance the immune 
response (26). AMP immunomodulatory functions might be as important as their direct 
antimicrobial activity in regards to patient defence (26). 
The another important soluble molecule reduced in preterms related to GA is circulating 
Mannose-Binding Lectin (MBL) pattern recognition receptor, MBL is central to a 
complement system that is distinct from the other two complement pathways (classical 
and alternative) that uses the lectin pathway to help with activation of the complement 
pathway and like the previous soluble molecules increase in levels with GA and 
postnatal age (21, 26). MBL also interacts with TLR pathway, by augmenting signalling 
of TLR2 and TLR6 (26). Genetic variants of MBL deficiency, occurring in 1% of 
12 | P a g e  
 
individuals, are associated with higher risk of serious bacterial infection and increased 
premature birth risk (26). Finally, deficiencies of MBL in the plasma is associated with 
neonates getting both EOS and LOS infections, neonatal pneumonia and requiring a 
prolonged period of antibiotic therapy (26). The deficiencies of the above soluble 
molecules lead to the inability for phagocytes to clear bacterial infection through 
phagocytosis (21).  
1.3.3 Preterm Cells Involved in Fighting Sepsis Infection: 
Cells involved in the innate immune response to bacterial infection are present in 
preterms but at lower levels compared to term infants and adults (26). Further, the 
preterms overall pool of phagocytic immune cells: neutrophils, monocytes/macrophages 
and DCs, and the pool of immune cell precursors is lower, due to reduced Granulocyte 
Colony Stimulating Factor and Granulocyte-Macrophage Colony Stimulating Factor 
levels and an inadequate storage due to preterms bone marrow storage capacity being 
lower than adults and even 20% lower than term infants (21, 39, 42).  
Preterm neutrophils adherence to the endothelium is also decreased due to low levels of 
adhering molecules Endothelial selectin, Placental selectin and Leukocyte selectin (E-
selectin, P-selectin and L-selectin respectively) compared to adults, this may impair 
neutrophil migration ability to the infection site as well (21, 39). Lack of actin filament 
formation once neutrophils are stimulated can also play a role in the inability of preterm 
neutrophils accessing infected sites as it means neutrophils become less deformable thus 
cannot cross the endothelial cell junctions (39). Beta-2-integrin Complement Receptor-3 
(CR3), also known as Macrophage antigen-1 and CD11b/CD18, functions as a sensor of 
pathogens on the phagocyte surface and have an additional role in binding complement, 
CR3 also works to facilitate adhesion of leukocytes, migration and activation, 
phagocytosis, activation of ROI, binds to LPS and other microbial surface components, 
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and triggers up-regulation of inducible Nitric Oxide Synthase and production of NO and 
broad range microbial product recognition (40, 43). It also recognises the Intercellular 
Adhesion Molecule 1/2 superfamily, the binding of these molecules yields firm 
neutrophil adhesion to the endothelium as a result (39). CR3 in term neonates is lower 
than adults, and preterms have shown CR3 levels even lower than term neonates, thus 
because of the impaired CR3 levels; neutrophil and monocyte activation and migration 
to the inflammation site is also impaired in preterms (39, 40, 43).  
C5a and its receptor C5aR when working together have the effect of redistributing 
blood flow, increased inflammation, aggregation of platelet cells and release of ROI 
(43). C5a-mediated local leukocyte activation has an effect similar to TLR stimulation 
in the form of cytokine production being increased and adhesion molecules being 
upregulated on the vascular endothelium, thus increasing the recruitment of cells to the 
infection site (39, 43). C5aR deficiency in term neonates when compared to adults may 
increase the likelihood of infection because there may be a limited response to C5a (43). 
C5a and C5Ar levels have been shown to be higher in preterms than term infants with 
sepsis and other co-morbidities such as respiratory disease that requires mechanical 
ventilation and necrotising enterocolitis all being associated with a systemic 
inflammatory response in preterms, being a likely contributor to the enhanced levels in 
the preterms Central Nervous System (44).     
Neutrophils themselves in preterms when compared to term infants and even adults 
have shown reduced intracellular bacterial killing ability through the respiratory burst, 
the production of ROS due to increased cellular metabolism of oxygen, neutrophils of 
preterms compared to term infants have also shown deficiency in increasing their 
respiratory activity when both groups cells have been stimulate by the presence of 
CONS bacterial species (39, 45) and decreased S. aureus killing (46). ROS can also 
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have a negative effect on preterm lungs due to diminished production of antioxidants 
and the accumulation of neutrophils (45). Preterm neutrophils have shown deficiencies 
in their bacterial killing ability through production and release of Neutrophil 
Extracellular Traps, comprised of granular and cytoplasmic proteins with 
Deoxyribonucleic Acid bound to them forming the lattices of the Neutrophil 
Extracellular Traps (21, 26).  
Monocytes, another cell type part of the innate immune response, are precursors for 
Macrophages with the ability to kill invading bacteria through phagocytosis and have a 
cytokine producing ability and DCs that have the ability to present antigens to the naïve 
T-cells through the MHC class II (21, 26, 39). Both monocytes and NK cells are also 
part of the innate immune response of preterms and, like neutrophils, are deficient in 
their function (21, 26, 39). Preterm monocytes are deficient in their ability to produce 
cytokines thus cannot activate adaptive immunity through signalling of these cytokines 
(21, 26, 39). Monocytes are also deficient in their ability to activate the adaptive 
immune response through the MHC class-II via upregulation of Human Leukocyte 
Antigen-antigen D-Related due to potential failure in regulation of MHC class-II 
expression, this implies a developmentally impaired innate/adaptive immune system 
interaction (21, 26, 39).  
NK cells are cytotoxic cells and a distinct subset of B/T-cells, their function being 
elimination of foreign bodies such as bacteria, fungi, parasites, virus infected cells, 
tumour cells, antibody sensitised cells and even some normal cells that are absent of 
previous sensitisation through lysis of target cells (39, 43, 47). NK cells role in preterm 
infant sepsis is poorly understood, what is known is preterm NK cells have shown a 
decreased cytotoxicity, and deficient overall numbers when compared to adult NK cells 
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(39, 43, 47). NK cells have shown to rise to appropriate adult levels between one week 
and 12 months of age even in preterms (39, 47). 
1.3.4 Preterm Cytokines Involved in The Immune Response to Sepsis Infection: 
Preterms suffer from lower Th-1 cytokine production from their monocytes, even 
compared to term infants and adults, due to a Th-2 bias response when developing in 
the mother to avoid maternal immune attack resulting in deleterious inflammation in the 
uterus and eventual foetal rejection (21, 26, 39). The cytokines found to be lower in 
preterms compared to term infants are TNF-α and IL-12, this bias causes preterms 
vulnerability to sepsis as the Th-2 response is anti-inflammatory producing anti-
inflammatory cytokines (IL-4, IL-5, IL-13 and IL-10) and the Th-1 response is 
inflammatory producing (IL-1β, IL-2, IL-6, IL-8, IL-12 and IL-19, INF-γ and TNF-α) 
with a lacking pro-inflammatory response such as INF-γ, preterms cannot properly 
identify and remove invading bacteria (21, 48-50). This is all linked to a reduced innate 
immune response with a decreased monocyte and neutrophil pool, the monocytes being 
responsible for activating the adaptive immune system (21, 26).  
1.4 Antibiotics Treat Bacteria and Regulate Inflammatory Cytokines: 
1.4.1 Antibiotics: 
There are two main types of antibiotics depending on their effect on bacterial growth 
(51, 52), they can also be divided into multiple categories based on structures and the 
specific bacterial cell site or system inhibited (53-56). The two main types are 
bacteriostatic and bactericidal (51). Bacteriostatic antibiotics inhibit bacterial growth 
keeping them in the stationary growth phase (51, 52), whereas bactericidal antibiotics 
kill >99.9% of the bacteria (51, 52). Bactericidal is more effective than bacteriostatic as 
one merely inhibits bacterial growth, requiring the immune system to clear the inhibited 
bacteria, and the other kills bacteria completely (51). 
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This is not always clear cut though, in culture conditions bactericidal antibiotics usually 
fail at killing every organism, potentially because the bacterial inoculum is too large to 
effectively kill it all within 18-24 hours (52). Bacteriostatic antibiotics may, after 18-24, 
kill more than 90-99% of bacteria but not enough for a bactericidal title (52). Growth 
conditions, bacterial density, antibiotic test duration, and the extent of bacterial number 
reduction may all influence the microbiological in vitro determination of whether an 
antibiotic is bacteriostatic or bactericidal (52). Even in the clinical sense, antibiotic 
classification is even more arbitrary, thus antibiotics are better classified as potentially 
both bacteriostatic and bactericidal (52).  
Antibiotics are a central part of paediatric and adult sepsis treatment with 
recommendations of empirical administration within one hour of causative bacteria 
identification (57). Though there is no relation to paediatric sepsis mortality due to 
antibiotic administration after three hours or more, it should be avoided as paediatrics 
have less organ failure free days (57). When there is a prolonged period before any 
antibiotic is administered in adults, there is a logarithmic relationship between mortality 
from sepsis, with an average 7.6% survival decrease every hour delayed treatment, and 
hypotension duration (57). Ceftriaxone and Vancomycin, can potentially have a 
regulatory effect on some crucial sepsis cytokines (TNFα, IL-1β, IL-6 and IL-10) in 
addition to their bacterial killing abilities (58-65).  
1.4.2 Ceftriaxone: 
Ceftriaxone, a member of the third generation cephalosporins β-lactam antibiotic group, 
is a bactericidal antibiotic that targets and disrupts cell membrane synthesis of bacteria 
via inhibition of enzymes used to synthesize the cell membrane peptidoglycan layer (55, 
66). Ceftriaxone works by targeting cross-linking peptidoglycan units through inhibition 
of transpeptidases, also called penicillin binding proteins, catalysed peptide bond 
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formation reaction (55). Inhibition works through a process called penicilloylation of 
the active site of penicillin binding protein’s transpeptidase (55). Due to β-lactam 
molecules having a cyclic amide ring and being a terminal D-alanyl-D-alanine dipeptide 
analogue of peptidoglycan, Ceftriaxone acts as a substrate in the acylation phase of 
cross-link formation for the enzyme, causing destabilisation of the enzyme due to 
inability to hydrolyse the bond, the now ring-opened drug has created (55). Third 
generation cephalosporins are resistant to bacteria inhibiting the characteristic β-Lactam 
ring through the enzyme β-lactamase to hydrolyse the peptide bond (67).             
1.4.3 Vancomycin:        
Vancomycin is part of the glycopeptide group of bactericidal antibiotics, this group 
inhibits the second stage of cell wall synthesis of susceptible bacteria, specifically 
inhibiting the peptidoglycan of the cell membrane (55, 68). Interference with cell wall 
synthesis causes bacteria to lyse, due to loss of strength from the cell membrane, from 
the resulting cellular stress responses and changes in shape and size of the membrane 
(55). Vancomycin can also potentially alter the bacterial membrane permeability and 
inhibiting synthesis of Ribonucleic Acid (68). Vancomycin is effective against GP 
bacteria only, due to low permeability (55). Vancomycin is a strong antibiotic with little 
to no resistance (68), however Vancomycin resistance has been found in some Gram-
positive Cocci, the first was a clinical isolate of Enterococcus, it was later found that 
MRSA from Michigan, Pennsylvania, and New York gained Vancomycin resistance 
from the transfer of the Vancomycin resistance gene vanA cluster from Enterococcus to 
MRSA (69).  
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1.5 Bacteria are Developing Resistance to the Antibiotic Treatment: 
1.5.1 Bacterial Antibiotic Resistance Mechanisms: 
Due to inappropriate use of antibiotics to treat bacterial infections and the resulting 
selection pressure in the bacterial environment, bacteria are constantly developing 
resistance to the antibiotics used to try to kill them (70). Resistance to at least one agent 
in three or more antibiotic categories are termed multidrug-resistance (MDR) bacteria 
(71). The methodology bacteria employ to resist antibiotics is through acquired 
resistance obtained through mutation of bacterial genes that is then passed on to other 
bacteria through transposons, bacteriophages and through transfer of bacterial plasmids 
(72). The other method is through intrinsic resistance, where bacteria already possess 
natural antibiotic resistance through their biology, such as E. coli having intrinsic 
resistance to vancomycin due to the molecule being unable to penetrate the outer 
membrane (OM) of GN bacteria (73, 74).  
The main mechanisms bacteria use to acquire resistance to antibiotics are as follows: 
GN bacteria may employ resistance through alterations to the OM permeability by 
either changing the porin channels that allow the antibiotic to enter the bacteria, as well 
as increasing the efflux of the antibiotic out of the bacteria so that the antibiotic cannot 
damage the bacteria (74).  
Other mechanisms employed by GP and GN bacteria are antibiotic inactivation by 
enzymes produced by the bacteria targeting specific key antibiotic areas, these enzymes 
are excreted from the cytoplasmic membrane of GP bacteria who have no OM, the 
enzymes are released into the extracellular environment, but for GN bacteria the 
enzymes are restricted to the periplasmic space (74, 75).  
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Another way bacteria gained resistance to antibiotics is altering the antibiotic target, due 
to some antibiotics having a specific target inside the bacteria, if that target is either no 
longer recognised or has a lower affinity for the antibiotic the bacteria can carry out its 
function unimpeded by the antibiotic presences (73, 74, 76). Bacteria can also generate 
alternative targets for the antibiotic or generate a new protein or entire metabolic 
pathway with the same function that the antibiotic does not recognise, while the still 
targeting the old protein (73, 74, 76). 
Finally, another affective resistance mechanism is through biofilms formation (77). A 
biofilm is a structure formed from a self-produced matrix of Deoxyribonucleic Acid, 
protein and polysaccharides with a consortium of bacteria embedded inside (77). Hiding 
inside a biofilm, bacteria are protected from both the hosts immune system and 
antibiotics, the biofilm acting as a non-selective physical barrier against these 
treatments, the above antibiotic mechanisms of bacteria also contribute to biofilm 
survival (77, 78). The resistance pattern of the causative bacteria isolated from the same 
study performed by Muhammed et al. (27) and Najeeb et al. (29) can be viewed in 
Table 4. (27, 29).  
Table 4. The antibiotic resistance patterns found in neonatal sepsis isolates (27, 29).  
 
From Table 4 varied resistance patterns of all the causative bacteria isolated can be 
observed due to inappropriate antibiotic use (27, 29). Less common antibiotics, such as 
amikacin and vancomycin, still have an effect (27, 29). Thus, new treatments must be 
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explored to either help resuscitate the antibiotics killing ability, as adjuncts to the 
antibiotics, or replace them as the treatment for bacteria as antibiotic alone are not 
sufficient anymore. Even when antibiotics do work, they may cause a more severe 
sepsis infection due to releasing pro-inflammatory bacterial cell components such as 
endotoxins (lipopolysaccharides) (79-81). 
1.6 Alternative Treatments for Sepsis: 
1.6.1 Potential Adjunct Treatments with/without Antibiotics:  
The main goal of sepsis treatment is to treat early with broad-spectrum antibiotics early, 
to use aggressive fluid resuscitation, control the source of the infection and finally to 
use vasopressors and ionotropic medication to provide cardiovascular support (82). 
There are many different methods that have been tried over the past several decades, 
due to antibiotic resistance being developed by bacteria, with varying successes (29, 
70). This can be viewed in Table 5 (Modified from (82)). 
Table 5. The different Treatments that have been tried to improve sepsis outcomes. 
Treatment Target for Treatment Results Reference 
Recombinant Tissue Factor 
Pathway Inhibitor (Tifacogin) 
Overactive Coagulation that 
takes place during sepsis 
No improvement in mortality (83) 
Recombinant Activated Protein C 
Drotrecogin Alfa (Activated)  
Both Coagulation and 
Inflammation during sepsis 
No improvement in mortality (84, 85)  
1. Granulocyte Macrophage-Colony 
Stimulating Factor  
2. Recombinant IL-7 
Stimulation of the Immune 
system 
1. Reversal of 
Immunoparalysis 
2. Reversal of T-lymphocyte 
apoptosis    
(82, 86-
88) 
Monoclonal Antibody and 
Polyclonal Antibody (AZD9773) 
Inhibition of Inflammatory 
cytokine TNF 
No improvement in mortality (89-92) 
Monoclonal Antibodies and 
Polyclonal Antibodies 
The Staphylococcal 
Enterotoxin K  
Both antibodies only effective 
as passive sepsis treatments 
(93, 94) 
 
From the results of Table 7 from different studies of different potential treatments for 
sepsis, it is clear that a new treatment is still needed. A combination of Antimicrobial 
Peptides of the body and antibiotics could provide the answer to bacterial sepsis. 
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1.7 Antimicrobial Peptides Effect on Bacteria: 
1.7.1 Antimicrobial Peptides (AMPs): 
Human AMPs are small (<10 kDa) molecules with ~10-50 residue amino acids (aa) and 
are part of innate immunity they inhibit, with varying degrees of broad-spectrum bio-
activity, multiple foreign bodies, such as bacteria, parasites, fungi and viruses. They can 
stop pathogens growth on skin and mucosal surfaces and dissemination to normally 
sterile sites (81, 95, 96). AMPs are produced by various cells including epithelial cells, 
intestinal Paneth cells, platelets, leukocytes (neutrophils, macrophages, monocytes, 
DCs, and mast cells), keratinocytes, mucosal epithelial cells, endothelial cells, and 
adipocytes and are found in body fluids and secretions (saliva, urine, sweat, and breast 
milk). The cationic AMPs are naturally attracted to the anionic bacterial cell surface 
composed of phospholipids including phosphatidylglycerol, cardiolipin, also known as 
diphosphatidylglycerol, and phosphatidylserine (81, 96).The net-neutral charged host 
cell surface from lipids phosphatidylcholine, phosphatidylethanolamine, sphingomyelin 
and sterols cholesterol, ergosterol allows AMPs some selectivity of their targets (96).  
AMPs are classified into four groups according to their secondary structure: α-helical 
peptides, β-sheet peptides, loop peptides, and extended peptides (96). Mammals 
produce two families of AMPs, the α-helical cathelicidins and the β-sheet stabilised 
defensins, which is further divided into either α-defensins or β-defensins based on the 
three disulphide bridge pattern formed. Humans defensins are ~30-40 aa residues long 
and are cytosine rich with six α-/β-defensins being produced. Humans produce LL-37 as 
the sole cathelicidin (96). AMPs are either induced from an infection response such as 
through pro-inflammatory cytokines and TLR signalling or constitutively expressed. 
Most AMPs they start as pro-peptides that, after undergoing subsequent proteolytic 
processing become mature bioactive peptides (96). While cationic AMPs are the largest 
22 | P a g e  
 
class, anionic AMPs such as dermcidin produced by the eccrine sweat gland contribute 
to host defence through the epithelium (96). AMPs integrate into the lipid bilayer of 
both GP and GN bacteria as AMPs have an amphipathic structure, hydrophobic and 
hydrophilic structure, resulting from separation of the hydrophobic and the polar or 
charged moieties (96). Once integrated they kill bacteria by cytoplasmic membrane 
perturbation causing pore formation in the bacterial cell membrane and thus causes 
destabilisation and rupturing of the bacterial cell or they can affect internal bacterial 
targets at micro-to-nanomolar concentrations (96). AMPs also regulate both pro-/anti-
inflammatory cytokines and chemokines, induce the migration of cells, cell survival and 
proliferation, some AMPs demonstrate wound healing abilities and angiogenesis (81, 
97-99). 
1.7.2 Bactericidal/Permeability Increasing Protein: 
BPI is a 55–60 kDa single-chain Cationic AMP of the lipid-transfer protein family, 
found in azurophilic granules of neutrophils, and both neutrophil and monocyte cell 
surfaces and the product of human mucosal epithelial cells, including the female 
urogenital tract (100). BPI shows high affinity, selectivity and potency for GN bacteria, 
by binding to the conserved lipid A moiety/inner core region of endotoxin of LPS, thus 
inhibiting all inflammatory responses to LPS including cytokine release, neutrophil 
oxidase enzyme activation and NO formation (100). Once BPI has bound to the GN 
bacteria OM, it penetrates into the inner membrane of GN bacteria, in a time dependent 
manner. It then causes damage the inner membrane and compromises the integrity 
resulting in death of GN bacteria (101). A recombinant 21 kDa version of BPI, rBPI21, 
has been found to have some effect on cell wall lacking Acholeplasma laidlawii, L-form 
GP bacteria, S. aureus and Streptococcus pyogenes, S. pneumoniae and American Type 
Culture Collection (ATCC) 25923 S. aureus compared to natural BPI that has little to 
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no affect against GP bacteria, this suggests that AMPs can be modified to have activity 
against bacteria they would normally have no activity against (102-104). These effects, 
are still limited as rBPI21 can only affect the previously mentioned bacteria through 
either inhibition of bacterial cell growth, enhancing immune cell activity against the 
bacteria or partial permeabilization enough to cause bacterial cell lysis (102-104).  
1.7.3 Lactoferrin: 
Lactoferrin (LF) is an 80kDa AMP non-haem iron binding glycoprotein that is part of 
the transferase family of proteins (105). LF is produced by many mammal species from 
mucosal epithelial cells and found in mucosal secretions of urine, vaginal fluids, semen, 
gastrointestinal fluids, bile, milk and colostrum, nasal and bronchial secretions, saliva 
and finally tears (105, 106). With milk and colostrum, LF is the second most abundant 
protein at 1g/L and 7g/L respectively behind caseins. Other locations within bodily 
fluids such as blood plasma, and amniotic fluids also contain LF. Finally, LF is found in 
secondary granules of neutrophils at 15µg/106 neutrophils (105, 106). LF is widely 
distributed in the body from the respiratory system, the gateway digestive system and 
the reproductive system, supporting LF having a part in humans immune defence (99).  
When subjected to sepsis, plasma levels of LF have been observed to increase from as 
low as 0.4-2 mg/L to as high as 200 mg/L (106). LF is delivered to inflammatory sites 
by neutrophils potentially providing cells a high concentration of LF on their surface 
(106). LF has a bacteriostatic and bactericidal ability in vitro (107) and bridges the 
innate/adaptive immune systems (108).  
LF iron binding robs bacteria of iron they need to grow in the body, LF can also bind to 
OM LPS inhibiting some enteropathic pathogens pathogenesis due to surface-expressed 
pathogenesis factors being interfered with (109). Binding to glycosaminoglycans of 
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proteoglycans enables protection from pathogens trying to invade host cells using 
glycosaminoglycans-pathogen interaction (106, 110, 111). 
1.7.4 LL-37: 
LL-37 is a naturally occurring Cationic AMP in humans that is produced by the C-
terminal of the Human Cationic Protein with a size of 18kDa (hCAP18), and is the only 
cathelicidin humans possess (81, 112, 113). Cells that make LL-37 are mainly epithelial 
cells, neutrophils and NK cells (81, 112). Normal LL-37 levels are 2µg/mL at epithelia 
expression sites, but when infection takes place the levels can increase two-three-fold 
(114). LL-37 has broad-spectrum effects against GP bacteria including S. aureus but 
less against MRSA and GN bacteria including E. coli (114). By interacting with anionic 
parts of the bacterial membrane, LL-37 causes membrane disruption changing lipid 
packing and organisation, forming pores and causing autolysis (112, 114). LL-37 also 
affects bacterial biofilm formation by decreasing bacterial cell attachment, stimulating 
twitching motility and down-regulating genes essential for biofilm development by 
influencing two major quorum-sensing systems (Las and Rhl) (114). LL-37 binds and 
inhibits GN bacteria LPS, and LPS Binding Protein an acute phase reactant present in 
blood that transfers LPS to CD14+ macrophages, the primary receptor, results in LPS-
induced αα inhibition and finally amelioration of sepsis (115). LL-37 inhibition of 
lipoteichoic acid (LTA), stops secondary inflammatory responses from LPS and LTA 
released from dead bacteria (114). LL-37 also supresses LPS-induced nuclear factor-
kap-paB subunit p50 and p65 translocation into monocyte and epithelial cell nuclei and 
inhibits DC activation with bacterial TLR (114).  
1.7.5 Innate Defence Regulator peptide-1018: 
Innate Defence Regulator peptide-1018 (IDR-1018), is a synthetic peptide made from 
bovine Host Defence Peptide (HDP) bactenecin derivative Bac2a (97). Developed, with 
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other synthetic peptides, through scrambling, deletions and point mutations of 
bactenecin to create a peptide (when compared to Bac2a) IDR-1018 has superior 
immunomodulatory effects; of the peptides tested IDR-1018 was found to have potent 
inducement of MCP-1/3 and a >50-fold increase in chemokines responsible for 
infection protection (97). IDR-1018 has superior effects compare to LL-37 and a ten-
fold increase in chemokine induction compared to IDR-1 (97). IDR-1018 cannot 
directly neutralise LPS as IDR-1018 cannot bind to LPS (97). IDR-1018 also has anti-
biofilm affects by stimulating degradation of the second messenger stress-induced 
nucleotides (p)ppGpp, involved in bacterial biofilm formation and maintenance (97). 
1.7.6 The Problems stopping AMPs being used as therapeutic treatments: 
The problems associated with AMPs being used as sepsis treatments include 
cytotoxicity in mammalian cells in large doses and their lack of target selectivity against 
microbes (116). Like their resistance to antibiotics, bacteria have developed resistance 
to AMPs and is thus another problem that must be understood and tackled if AMPs are 
to become an effective treatment for preterm sepsis (96, 117-120). 
1.8 Bacterial Resistance to AMPs: 
1.8.1 Methods Used by Bacteria to Resist AMPs: 
Like antibiotic resistance, bacteria developed resistance mechanisms allowing them to 
avoid deadly AMP attack, when AMPs are unable to kill bacteria, through either barrier 
defence of phagocytic killing, the remaining defences may not be enough to clear the 
bacteria (96, 117). AMP resistance mechanisms include altering bacterial surface 
charge, external sequestration by secreted or surface associated molecules, an energy 
dependent membrane efflux pump, degradation of peptidase, and down-regulation of  
host AMP production (96).  
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Cell membrane access is limited for AMPs. Even though GP bacteria lack an OM they 
do have a thick peptidoglycan cell wall containing cross links of either Teichoic Acid 
(TA) or LTA (96). GN bacteria have an OM and a space between the OM and inner 
membrane called the periplasm that provides protection to GN bacteria through 
sequestration of potentially harmful molecules (121). In addition, large capsular 
polysaccharides and surface associated proteins make AMP cytoplasmic membrane 
access difficult (96). Capsular polysaccharides protect GP and GN bacteria from AMPs 
by either binding to the AMPs, or repelling the AMPs by electrostatic repulsion (96, 
118, 119). The more capsular polysaccharides there are the less able the AMPs are to 
bind the bacteria because of the capsular polysaccharides (118). Altering surface charge 
from anionic to more cationic allows bacteria to avoid cationic AMPs, this is a common 
strategy used by both GP and GN bacteria (96).  
GN bacteria can avoid AMPs by altering the anionic charge of LPS lipid A by: 1) 
acylation of GN bacteria OM phospholipids reducing/masking anionic charge, and 2) by 
increasing hydrophobicity and decreasing the membrane permeability of GN bacteria 
LPS lipid A through palmitoylation or acylation and Lipooligosaccharide (LOS) 
acylation of LPS oligosaccharide (96, 117, 118, 120). Increasing bacterial membrane 
acute repair mechanism, by facilitating membrane repair once damaged by host AMPs 
(118). Some GP bacteria alter anionic charge through TA modification by LTA 
insertion, through D-alanylation (this can also increase peptidoglycan sacculus density) 
and aminoacylation or lysinylation (96, 119).  
Bacteria can neutralise AMPs by indirectly releasing AMPs bound to the bacterial cell 
surface, or use associated polysaccharides and proteins either secreted into the 
extracellular milieu or part of the bacterial cell surface to bind and sequester AMPs, 
thus directly blocking bacterial cytoplasmic membrane access and stopping lytic pores 
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forming (96). Biofilms are another mechanism that protects bacteria from AMP attack, 
it works by providing the bacteria a resilient structure that is resistant to destruction 
from high AMP concentrations (118).     
AMP production down-regulation and either decreased or increased bacterial 
recognition, can allow some bacteria to resist AMPs in intestinal epithelial cells and 
promoting gastrointestinal tract invasion, colonisation and survival (96). By increasing 
host cysteine proteases or by using exotoxins, constitutive incorporation of L-Ara4N 
into LPS and in a temperature-dependent manner, under stress conditions, modification 
of lipid A, by removal of a single phosphate group from lipid A and incorporation of a 
seventh acyl chain in lipid A respectively, can either increase or decrease TLR4 
recognition, activation and signalling, both mechanisms are required for AMP 
resistance (96, 118). Conversely increased inflammation and TLR4 detection may 
provide resistance to AMPs and increased pathogenesis (118). CRISPER-Cas protein 
Cas9 repression of bacterial lipoprotein, causes enhanced polymyxin B resistance and 
direct TLR2 ligand suppression resulting in signal evasion, this includes induction of 
AMPs, by the host receptor (118).    
Both GP and GN bacteria release proteases, degrading AMPs before they can affect the 
bacteria (119). Enzymes with broad substrate activity against AMPs, such as 
extracellular metallopeptidase gelatinase, aureolysin, elastase, alkaline phosphatase, 
Zinc-dependant Metalloprotease A/B, OM protease OmpT, SepA, Streptococcal 
Pyrogenic Endotoxin B, ZapA and Group A Streptococcus secreted plasminogen-
activating streptokinase, are ones that can combat the AMPs relative resistance to 
protease degradation, and are found in mammalian pathogens typically with 
metallopeptidases and cysteine proteases being included (96, 118, 119, 122). Some 
bacteria can cause macrophages to release proteolytic cathepsins to degrade Human β 
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Defensins from LPS activation of pro-inflammatory cytokines (INF-γ and IL-13) (118). 
Finally, another resistance mechanism similar to antibiotic resistance, is AMP removal 
from bacteria through efflux pumps (96, 117-120).  
1.9 AMPs May Help Antibiotics to Kill the Bacteria: 
1.9.1 The Synergy Between AMPs and Antibiotics:  
Combination treatments against bacteria can be either additive (equal to the sum of the 
components), synergistic (greater than the sum of the components) or antagonistic (less 
than the separate treatments) (55), synergy can also be determined from a Fractional 
Inhibitory Concentration (FIC) of ≤0.5 (123). The combination treatment of AMPs and 
antibiotics has been reported as a potentially synergistic one (124), with AMPs reducing 
the required antibiotic dose to kill bacteria. this is potentially achieved either through 
AMPs augmenting the antibiotics activity when the two share similar targets, or the 
AMPs provide bacterial access for the antibiotics by working in series (124-126). A 
summary of some of the AMPs and antibiotics synergistic effects against different 
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Table 6. Summary of some AMP and antibiotic combinations against different bacteria.  
AMP/Antibiotic 
Combinations  
Bacteria/s Tested Result Reference 
WR12 and D-IK8 with 





Methicillin Sensitive S. aureus, MRSA, 
Vancomycin Resistant S. aureus and 
Methicillin Resistant S. epidermidis. 
Both WR12 and D-IK8 with 
Fusidic acid, Mupirocin and 
Daptomycin were all 
synergistic against all the 
bacteria tested 
(127) 
LL-37 with Azithromycin,  P. aeruginosa (PA01), K. pneumoniae 
K700603, A. baumannii AB19606, 
Human clinical MDR P. aeruginosa 
P4, K. pneumoniae K1100 and MDR A. 
baumannii AB5075 
Synergy was observed 
between LL-37 and 
Azithromycin against all the 
bacteria tested 
(128) 
PL-5,18,26,29,31 and 32 




ATCC: E. coli 25922, P. aeruginosa 
27853, K. pneumoniae 700603, S. 
aureus 25923, S. epidermidis 12228 
and S. pneumoniae 49619 
PL-5,18,26,29,31 and 32 
combined with Vancomycin 
were all synergistic against S. 
aureus 25923, S. epidermidis 
12228 and S. pneumoniae 
49619 
(129) 
Novicidin with Rifampin, 
Ceftriaxone, Ceftazidime, 
Cefixime and Cefotaxime 
61 E. coli isolates, 33 Klebsiella-
Enterobacter-Serratia group isolates, 7 
strains with bla(New Delhi metallo-β-lactamase)-
harbouring plasmid ATCC BAA-2468 
is Enterobacter cloacae, BAA-2469/-
2471 are E. coli, and BAA-2470/-
2472/-2473 and National Collection of 
Type Cultures 13443 is K. pneumoniae 
Novicidin and Rifampin were 
synergistic against >70% of 
the strains. Novicidin and 
Ceftriaxone or Ceftazidime 
were synergistic 
against 89.7% of 
Ceftriaxone-resistant strains 
and 94.1% of Ceftazidime-
resistant strains respectively 
(130) 




Clinical strains: S. aureus, P. 
aeruginosa, A. baumannii, and E. coli 
DP7 and Vancomycin and 
DP7 and Azithromycin were 
the most effective 
combinations tested 
(131) 
Nisin Z, Pediocin PA-
1/AcH and Colistin with 
Ampicillin, 
Chloramphenicol, 




P. fluorescens Nisin/Ampicillin (FIC=1.3), 
Pediocin PA-1/Tetracycline 
(FIC=0.75) and 
Colistin/Ampicillin were the 









Nalidixic acid, Netilmicin, 
Oxacillin, Rifampicin, 
Streptomycin, Tazocin and 
Tetracycline 
ATCC E. coli 25922 Synergy was observed 
between Esc(1-18) and 
Cephalosporin C, 
Erythromycin, Nalidixic acid, 
Netilmicin and Rifampicin 
(133) 
FIC: (≤0.5) = Synergy, (0.5< FIC ≥1) = Additive, (1<FIC≤2) = Indifference and (FIC>2) = antagonism *: Esc(1-18)/Erythromycin 
combination of particular interest due to having the lowest FIC. 
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From Table 6 synergy can be observed between different AMPs and antibiotics and 
even though combination treatment have shown to be effective against many different 
bacteria presently, due to AMP clinical trials focussing as topical formulation 
treatments and few treatments for the paediatric population (134) and limited in terms 
of sepsis treatment (135). There is one study that has tested the combination of AMPs 
and antibiotics in human whole blood (136). However, the combinations of LL-37, LF 
and IDR-1018 with either Ceftriaxone or Vancomycin have not been tested against 
clinical isolates of neonatal sepsis causing bacteria in human whole blood. As most 
studies including the one is Table 6 have used artificial media instead of blood. 
1.9.2 Project Aims and Hypotheses: 
From this project, the optimum combination of AMPs (LF, LL-37, IDR-1018 and 
rBPI21) and antibiotics (Vancomycin and Ceftriaxone) will be determined from testing 
known sensitive and resistant preterm infant sepsis causing clinical isolates (S. aureus, 
MRSA, E. coli and ESBL E. coli), when added to donated healthy adult blood serving as 
a preterm infant sepsis model. 
Specifically, the aim and hypothesis of this project is as follows: 
Aim: To test different combinations of AMPs and antibiotics for their ability to kill 
resistant and non-resistant sepsis causing bacteria.  
Hypothesis: There will be an optimal combination of AMPs and antibiotics that will 
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2 Chapter 2 Materials and Methods: 
2.1 Table 7. Bacteria used in this project: 
Species Strain Supplier Origin 
S. epidermidis Clinical 
Strain 





Sepsis Neonate, King Edward 













Sepsis Neonate, King Edward 
Memorial Hospital Clinical 
Isolate 
S. aureus  Clinical 
Strain 





Sepsis Neonate, King Edward 









Sepsis Neonate, King Edward 
Memorial Hospital Clinical 
Isolate 
E. coli Clinical 
Strain 





Sepsis Neonate, King Edward 
Memorial Hospital Clinical 
Isolate 
ESBL E. coli Clinical 
Strain 





Sepsis Neonate, King Edward 
Memorial Hospital Clinical 
Isolate 









ATCC Clinical Isolate 









ATCC Clinical Isolate 
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2.2 Table 8. AMPs used in this project: 
AMP Name Type Reconstitution 
Liquid 
Origin 





























All AMPs were stored at -20ºC 
2.3 Table 9. Antibiotics used in this project: 
Antibiotic 
(Lot number) 




































All antibiotics and bacteria were stored at -80ºC 
2.4 Donors for the Project: 
Approximately, 10mL of blood was taken from voluntary recruited healthy adult donors 
by veno-puncture, and collected into sterile 3.8% Sodium Citrate 9 mL blood tubes 
(Vacuette) by a trained phlebotomist in accordance to ethics approval from Murdoch 
University Ethics (Project Number: 2016/031). The blood sample was kept at room 
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temperature with gentile rocking to stop the blood from coagulating prior to use. 
Experimental replication for sections (2.13 and 2.14) was performed by acquiring new 
donor blood samples after the current donor blood sample acquired for sections (2.13 
and 2.14) was used.  
2.5 Reconstitution of Antibiotics: 
The three antibiotics used (see Table 9) were reconstituted from their powder form 
using the following formula: 
Volume (mL) = Weight (mg) x Antibiotic Potency (µg/mg)/Concentration (µg/ mL) 
from the Clinical and Laboratory Standards Institute (CLSI). The potency was 
determined using the Lot number of the antibiotic on the Sigma-Aldrich website based 
on the antibiotics certificate of analysis. Ceftriaxone (see Table 9), Ceftriaxone required 
further steps to reconstitute as the potency needed to be determined by the following 
calculations: 
Active Fraction=Molar Mass(antibiotic weight without salt)/Molecular Weight 
(antibiotic weight with salt), then the Potency of Ceftriaxone was calculated by: 
Potency=(Purity)x(Active Fraction)x(1-Water Content).  
All variables for the calculations were viewed from the certificate of analysis of 
Ceftriaxone (Sigma Aldritch), and from these calculations the reconstitution volume 
determined. Piperacillin and Tazobactam reconstitution required the same calculations 
as Ceftriaxone to determine their potency and active fraction before the reconstitution 
volume could be determined. Once reconstituted, Piperacillin and Tazobactam were 
kept separate, all the other reconstituted antibiotics at -80ºC until needed. 
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2.6 Reconstitution of Lyophilised LL-37: 
BPI, LF, IDR-1018 and ScLL-37 (see Table 8) all came pre-prepared from PMH. 
Lyophilised LL-37 (see Table 8) came in a 2.5mg vial and was reconstituted to 
5mg/mL using sterile PBS. LL-37 was then left on ice for 20 minutes to ensure the LL-
37 powder was completely dissolved. All AMPs were stored at -20ºC until needed for 
the AMP/antibiotic combination experiment. 
2.7 Broth Used for Bacterial Culture: 
Tryptone Soya Broth (TSB) (Oxoid) and Cation Adjusted-Mueller Hinton Broth (CA-
MHB) (BBL) were both prepared according to the manufacturer’s instructions. For the 
TSB, 12g of TSB powder was suspended in 400mL of sterile water (Baxter) and mixed 
until the powder dissolved in the water, the broth was then autoclaved for 15 minutes at 
121ºC. For the CA-MHB, 6.6g of powder was suspended in 300mL of sterile water and 
mixed while heating the solution at ~53ºC then finally boiling the solution at 100-112ºC 
for 1 minute to completely dissolve the powder in the water. The solution was then 
autoclaved at 116ºC for 10 minutes. The pH of the CA-MHB was checked and adjusted 
to a pH between 7.2 and 7.4 if required. Both broths were stored at 4ºC until use. 
2.8 RPMI + 5% TSB Used for Bacterial Culture: 
RPMI + 5% TSB (RT5) media was prepared by adding 25mL of TSB broth (section 
2.6) to 475mL of RPMI 1640 media (Sigma/Thermofisher) with Sodium Bicarbonate 
and with L-glutamine and later RT5 was prepared in RPMI 1640 media 
(Sigma/Thermofisher) with Sodium Bicarbonate (section 2.13) and without L-glutamine 
(section 2.14). RT5 was stored at 4ºC until use. 
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2.9 Sub-culturing of Bacterial Stocks: 
Sub-culturing of the bacteria for use in the project was done on Columbia sheep blood 
agar (Thermo scientific) or TSA plates with sheep blood added to them (Thermo 
scientific). Bacteria from stock cultures were streaked out using standard 
microbiological techniques and all plates were incubated at 37ºC for at least 18 hours 
before they were taken out and placed into the fridge to be stored before use in future 
experiments. All plates were kept at 4ºC until the expiry date of the plates was reached 
and until use.   
2.10 Growth Curves and Mid-Log Stocks: 
From the initial bacterial plates that were received from Princess Margret hospital 
PathWest, growth curves were generated by inoculating 15ml of Tryptone Soy Broth 
with 3 colonies of each bacteria and incubated for 18 hours, then the next day 800ul of 
18-hour cultures were measured at 600nm using a spectrophotometer. Once the mid-log 
point was found for each bacteria, the bacteria were then placed in growth media 
containing 25% glycerol and stored at -80ºC for future use in the project. 
2.11 Viability Checks for the Mid-Log Bacterial Stocks: 
A viability check was performed on the bacteria once the stocks were made. New 
bacterial stocks were washed three times in 900µL of PBS and then resuspended in 
900µL of PBS and then serially diluted, in PBS, using 10-fold dilutions, to give a 1:10 
to 1:106 dilution of the bacteria. Once the dilutions were complete, the dilutions were 
then plated out at a volume of 10µL in triplicate onto sheep blood agar plates divided 
into six sections and once the spots dried the plates were parafilmed and placed into a 
37ºC incubator for at least 18 hours overnight to allow the bacteria to grow. After the 
incubation period, the dilution section with at least 10 and up to 80 colonies present 
were counted and the concentration of the bacteria was calculated using the formulas: 
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Colony Forming Units (CFU)/mL=(Average colony count)x100x10(the dilution factor)  
The process was repeated when checking the bacterial mid-log stocks viability in the 
subsequent experiment sections (2.12, 2.13 and 2.14). After some time, the wash step 
was introducing too much variability in the mid-log bacterial viability determination, 
this step was subsequently removed, and a viability check was performed on the 
bacterial mid-log stocks after thawing for 10 minutes in the 37ºC incubator with 
improved reproducibility. 
When counting the number of bacterial colonies at different time points in experiment 
sections (2.13 and 2.14) after the same triplicate plating method on sheep blood agar 
was performed pipetting 10µL the following calculations were performed: 
CFU/mL=(Average colony count)x100x7.5(the dilution factor) 
2.12 Minimum Inhibitory Concentration of Antibiotics: 
The MIC experiment was conducted according to CLSI procedure M07-A10 to 
determine the minimum concentration of antibiotics that would completely inhibit the 
bacteria to be used in the project compared to ATCC strains of known antibiotic 
sensitivity (see Table 7). See section (2.9) for sub-culturing procedure, this was done 
twice to ensure the bacteria were fully active after being frozen. Serial dilutions of the 
antibiotics vancomycin, gentamicin, ceftriaxone and piperacillin-tazobactam from the 
highest final concentration 512µg/mL to the lowest 0.125µg/mL (Tazobactam had a 
fixed concentration of 4µg/mL) were made on sterile polystyrene plates. Each antibiotic 
stock was thawed in a 37 ºC incubator for 12 minutes where a tiny ice pellet was visible 
that was taken to the PC2 hood and thawed.  
To make the serial dilutions of the antibiotics, 2x concentrations were made using a 1:5 
dilutions in CA-MHB. The bacteria were made to a 0.5 McFarland standard with the 
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Optical Density of each bacteria being between 0.08-0.13 when measured at 625nm. 
The bacteria were then made into 2x concentration using 0.05mL of bacteria in 4.95mL 
of CA-MHB, so that when the bacteria were added to the wells of 96 well plate for the 
MIC both the antibiotic and the bacterial concentration would be diluted to 1x 
concentration. Each isolate bacteria was run in duplicate on a 96-well plate. Once the 
bacteria were inoculated into the appropriate wells of the plate the bacteria were 
incubated at 37ºC for at least 18 hours. The plate was then taken to a spectrophotometer 
that could read 96-well plates and measured at an OD of 625nm to determine the MIC 
curve of the bacteria on the plate. Ultimately, a Vancomycin dose of 20µg/mL and a 
Ceftriaxone dose of 156µg/mL was chosen for section (2.14) experiment. 
2.13 Bacteriostasis Experiments: 
To determine the appropriate dose of bacteria in blood to be used in the main 
experiment, a bacteriostasis experiment was carried out to find the bacteriostatic point 
of S. aureus, MRSA, E. coli and ESBL E. coli (and initially S. epidermidis and CONS 
HVISE). See sections (3.3 and 3.4 (Figures 5-16)) for the different blood volumes and 
the mid-log bacterial dose concentrations investigated. The mid-log bacterial stocks 
were resuspended in the required volume of PBS to get the bacteria to the desired 
concentrations to be inoculated into the blood. RT5 was added to the appropriate wells 
of the 96-well polypropylene plate followed by desired volume of blood, and finally the 
bacteria, 20µL initially then later changed to 10µL, all totalled to a volume or 150µL 
initially then later changed to 75µL, the plate was then incubated for 18 hours at 37ºC 
with 5% CO2.  
The bacteria in this experiment were serially diluted 10µL:65µL six times, the first well 
containing sterile water to lyse the blood cells the other five wells contained RT5, to 
give a 1:7.5 to 1:1.78x105 dilution of the bacteria. See section (2.11) for 1:7.5 bacterial 
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colony counting method. It was decided that a shorter incubation time of 3 hours was 
required to stop either the blood from killing the bacteria or the bacteria outgrowing the 
control of the blood. Ultimately the final concentrations of 1x104, 1x106, 5x106 and 
1x107 CFU/mL were chosen for S. aureus, MRSA, E. coli and ESBL E. coli respectively 
inoculated at 10µL, a blood volume of 15µL and a total volume of 75µL for section 
(2.14) experiment. 
2.14 Combination of Antibiotics and Antimicrobial Peptides Experiment: 
Using an optimised protocol (Caitlyn Granland), the five different AMPs were 
inoculated with the two antibiotics and used to treat the bacteria (different combinations 
of Vancomycin and the AMPs for sensitive and resistant E. coli species) and (different 
combinations of Ceftriaxone and the AMPs for sensitive and resistant S. aureus 
species). Appropriate volumes of RT5 were added to the wells of the 96-well 
polypropylene treatment plate, next all AMPs (see Table 7) and Vancomycin and 
Ceftriaxone were diluted to the appropriate working concentrations before inoculating 
5µL of each into the appropriate wells of the treatment plate, the final concentrations in 
the wells being 50µg/mL (LL-37, ScLL-37, rBPI21 and IDR-1018) 100µg/mL (LF) 
respectively, see section (2.12). And the final concentrations of Vancomycin were 
20µg/mL and for Ceftriaxone was 156µg/mL, followed by 15µL of blood. Finally, 
10µL of the bacteria when inoculated into the blood were at their final concentrations of 
1x104, 1x106, 5x106 and 1x107 CFU/mL were chosen for S. aureus, MRSA, E. coli and 
ESBL E. coli respectively. Bacterial density was determined as per sections (2.11 and 
2.13). 
2.15 Statistical Test Conducted on the Resulting Data: 
A Friedman test (Non-parametric one-way ANOVA), with Dunn’s Multiple 
Comparisons was used to determine if there is a significant difference between the 
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combination of AMP/antibiotic treatment with respective monotherapies of AMPs in 
the 3-hour Blood bacterial count. A Mann-Whitney test (Non-parametric t-test) was 
conducted to compare the AMP/antibiotic combination and the monotherapies that 
showed significant reduction in bacterial growth compared to time 3-hour Blood 
bacterial count. The data was analysed using Graphpad Prism 7 were significance will 
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3 Chapter 3 Results: 
3.1 Growth Curves of Sensitive and Resistant Sepsis Causing Bacteria: 
The growth rates of the sensitive bacteria (E. coli, S. aureus and S. epidermidis) and the 
respective resistant strains (ESBL E. coli, MRSA and CONS HVISE) had similar growth 
rates and mid-log points as shown by the dotted lines (Figure 1), see section (2.10) for 
growth curve procedure. E. coli and ESBL E. coli at a bacterial density of 0.5210 and 
0.4492 respectively both reached these values at 85 minutes. S. aureus and MRSA at a 
bacterial density of 0.5660 and 0.6145 respectively both reached these values at 125 
minutes. Finally, S. epidermidis and CONS HVISE at a bacterial density of 0.5463 and 
0.5085 respectively both reached these values at 160 minutes. 
3.2 Minimum Inhibitory Concentrations of Sensitive and Resistant Sepsis 
Causing Bacteria:  
By determining the antibiotic sensitivity pattern of the sensitive and resistant clinical 
isolate bacteria, it assured resistant bacteria were only treated with antibiotics they were 
resistant to moving forward. See section (2.12) for MIC procedure with quality control 
strains ATCC E. coli 25922 and ATCC S. aureus 25923 with known sensitivities to 
antibiotics being tested (data for ATCC strains not shown to allow for clarity of the 
graph), the MIC values obtained after measuring the bacterial density at 625nm were 
compared against the ATCC bacterial MIC (see Table 7) using both CLSI M100-S25 
Performance Standards for Antimicrobial Susceptibility Testing and the European 
Committee on Antimicrobial Susceptibility Testing (Eucast2) website MIC database to 
confirm susceptibility. The respective Ceftriaxone, Gentamicin, Piperacillin-
Tazobactam, Piperacillin-Tazobactam 2 and Vancomycin MICs found for ATCC 25922 
E. coli are (0.5, 1, 2/0.031, 2/2, 512µg/mL) and ATCC 25923 S. aureus are (16, 0.25, 
0.5/0.0078, 0.5/2, 2µg/mL), Ceftriaxone against ATCC 25923 S. aureus was the only 
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MIC higher than the CLSI M100-S25 range and Vancomycin is not tested against 
ATCC 25922 E. coli. The MIC values for Ceftriaxone, Gentamicin, Piperacillin-
Tazobactam, Piperacillin-Tazobactam 2 and Vancomycin respectively for clinical 
isolates E. coli and ESBL E. coli at a bacterial density of 625nm are (0.5, 1, 128/2, 32/2 
and 512 µg/mL) and (>512, 128, 16/0.25, 16/2 and 512 µg/mL) respectively (Figure 2). 
(Note: Vancomycin is not used for E. coli MIC as these bacteria have an intrinsic 
resistance to Vancomycin as it cannot penetrate the bacterial OM).  
MIC values for Ceftriaxone, Gentamicin, Piperacillin-Tazobactam, Piperacillin-
Tazobactam 2 and Vancomycin respectively for clinical isolates S. aureus and MRSA at 
a bacterial density of 625nm are (32, 1, 16/.25, 2/2 and 1 µg/mL) and (256, 0.5, 32/0.5, 
8/2 and 1 µg/mL) respectively (Figure 3). Finally, the Vancomycin MIC values for 
clinical isolates S. epidermidis and CONS HVISE at a bacterial density of 625nm were 
(2 µg/mL and 4 µg/mL) respectively. Once again ATCC S. aureus showed the same 
Vancomycin MIC value (≤2 µg/mL), this meant both S. epidermidis and CONS HVISE 
were sensitive to Vancomycin. These results, compared to CLSI M100-S25 and Eucast2 
MIC values for confirm E. coli, ESBL E. coli, S. aureus and MRSA have sensitivity and 
resistance to some of the antibiotics tested. The plasma concentration 20µg/mL 
(Vancomycin) and average plasma concentration 156µg/mL (Ceftriaxone), both also 
being sub-inhibitory concentrations for E. coli, ESBL E. coli and MRSA, were chosen 
for section (2.14) experiment.  
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Figure 1: Growth and Mid-log point of bacterial clinical isolates. 
A-C: (E. coli and ESBL E. coli), (S. aureus and MRSA) and (S. epidermidis and 
CONS HVISE). Data shown is the mean of the triplicate optical density measurement 
of the single experiment performed on clinical isolate bacterial samples. Dashed lines 
show the mid-log points of each bacteria.  
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Figure 2: Minimum Inhibitory Concentrations (MIC) of Antibiotics against 
clinical isolates of sensitive and resistant bacteria. 
A-E: Ceftriaxone, Gentamicin, Piperacillin-Tazobactam, Piperacillin-Tazobactam 2 
and Vancomycin. Data shown is the mean and standard deviation optical density of 
the duplicate measurements at 625nm clinical isolate bacterial samples of E. coli and 
ESBL E. coli. 
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Figure 3: Minimum Inhibitory Concentrations (MIC) of Antibiotics against 
clinical isolates of sensitive and resistant bacteria. 
A-E: Ceftriaxone, Gentamicin, Piperacillin-Tazobactam, Piperacillin-Tazobactam 2 
and Vancomycin. Data shown is the mean and standard deviation optical density of 
the duplicate measurements at 625nm clinical isolate bacterial samples of S. aureus 
and MRSA. 
















































Figure 4: Minimum Inhibitory Concentrations (MIC) of Antibiotics against 
clinical isolates of sensitive and resistant bacteria. 
Data shown is the mean and standard deviation optical density of the duplicate 
measurements at 625nm clinical isolate bacterial samples of S. epidermidis and 
CONS HVISE. 
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3.3 Determining Bacteriostasis Using Different Blood Volumes and Bacterial 
Concentrations: 
A bacteriostasis experiment was performed, see section (2.13) for bacteriostasis 
procedure, to determine to optimum blood volume (30, 50 and 110µL) and starting 
inoculum (1x106, 1x107 and 5x107 CFU/mL) (Figure 5) to achieve bacteriostasis. Only 
S. epidermidis (5x107 CFU/mL), in 30µL of blood was found to be bacteriostatic after 
18 hours of incubation. However due to CONS HVISE not being resistant to 
Vancomycin from section (3.2) both S. epidermidis and CONS HVISE were removed 
from the study. 
We then used lower bacterial concentrations (1x105, 5x105 and 1x106 CFU/mL) 
inoculated into the same blood volumes (30, 50 and 110µL) to achieve bacteriostasis for 
E. coli, ESBL E. coli, S. aureus and MRSA (Figure 6) and (Figure 7). E. coli at 5x105 
CFU/mL in 50µL of blood was the only combination of bacterial concentration and 
blood volume tested showing bacteriostasis after 18 hours of incubation growing by <1-
log from the starting inoculum (Figure 6). Of the S. aureus and MRSA tested, MRSA at 
5x105 CFU/mL and 1x106 CFU/mL in 50µL and 110µL of blood were the only 
combination of variables, 5x105 CFU/mL and 1x106 CFU/mL in 50µL both growing by 
a ½-log and for 5x105 CFU/mL and 1x106 CFU/mL in 110µL both growing 1-log 
(Figure 7), to begin to show bacteriostasis. 
To confirm the results obtained for E. coli and ESBL E. coli, a repeat experiment on E. 
coli and ESBL E. coli at the bacterial concentrations (1x105, 5x105 and 1x106 CFU/mL) 
in the same blood volumes (30, 50 and 110µL) was conducted (Figure 8). Bacteriostasis 
was not achieved for any of the bacterial concentration or blood volume conditions 
tested in this experiment. 
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Figure 5: The Effect of Different Blood Volumes and Starting Inoculums on 
Bacteriostasis. 
Data shown is the 18-hour bacterial growth of clinical isolates of sensitive bacteria (S. 
aureus, S. epidermidis and E. coli). The dotted line represents the Time 0 inoculation 
of the bacteria and the solid line represents the Time 18 RT5 bacterial count in one 
donor.  



















































































































































































































































































































































































































































































































Figure 6: The Effect of Different Blood Volumes and Different Lower Starting 
Inoculums on Bacteriostasis of Different Bacterial Concentrations Second 
Attempt. 
Data shows the 18-hour bacterial growth of 1-log lower starting inoculum clinical 
isolate, both sensitive and resistant, bacteria (E. coli and ESBL E. coli) of the second 
bacteriostasis experiment. The dotted line represents the initial T0 bacterial 
inoculation and the solid line represents the T18 RT5 count in one donor. 
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Figure 7: The Effect of Different Blood Volumes and Different Lower Starting 
Inoculums on Bacteriostasis. 
Data shows the 18-hour bacterial growth of 1-log lower starting inoculum clinical 
isolate, both sensitive and resistant, bacteria (S. aureus and MRSA) of the second 
bacteriostasis experiment. The dotted line represents the initial Time 0 inoculation of 
the bacteria and the solid line represents the RT5 Time 18 count in one donor. 
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Figure 8: Repeat Experiment on the Effects the Varying Volumes of Blood on 
the Bacteriostasis on Different Concentrations of E. coli and ESBL E. coli. 
Data shows the confirmed effect blood had on the sensitive and resistant clinical 
isolates of bacteria (E. coli and ESBL E. coli). The dotted line represents the initial 
Time 0 inoculation of the bacteria and the solid line represents the RT5 Time 18 
count in one donor. 
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3.4 Determining Bacteriostasis Using Different Bacterial Concentrations in a 
Fixed Blood Volume: 
A fixed blood volume of 15µL inoculated with various initial concentrations of E. coli, 
ESBL E. coli, S. aureus and MRSA (Figures 9-14) to achieve bacteriostasis was tested. 
When the different bacterial doses for E. coli (5x104, 1x105, 5x105 and 1x106 CFU/mL) 
as well as for S. aureus and MRSA and the bacterial doses for ESBL E. coli (5x105, 
1x106, 5x106 and 1x107 CFU/mL) were inoculated into the blood (Figures 9-10) showed 
that only S. aureus (5x105 and 1x106 CFU/mL) and ESBL E. coli (5x105 CFU/mL) 
showed bacteriostasis by either only growing by a ½-log or being inhibited by less than 
a ½-log respectively. 
Following from the last experiment, it was hypothesised a log reduction in bacterial 
inoculum ranges (5x103, 1x104, 2.5x104 and 5x104 CFU/mL) for E. coli as well as S. 
aureus and MRSA in 15µL of blood would achieve bacteriostasis for these bacteria, and 
that ESBL E. coli (5x105 CFU/mL) is bacteriostatic. Bacteriostasis was not achieved for 
any of the bacteria at any of the concentrations tested (Figure 11 and Figure 12), and 
repeated ESBL E. coli (5x105 CFU/mL) was found to not be bacteriostatic in the donor 
blood sample tested (Figure 11). 
To confirms the results observed for E. coli, ESBL E. coli, S. aureus and MRSA, a repeat 
experiment was conducted on the in bacterial inoculum ranges (5x103, 1x104, 2.5x104 
and 5x104 CFU/mL) for E. coli, S. aureus and MRSA and ESBL E. coli (5x105 
CFU/mL) (Figure 13 and Figure 14). Bacteriostasis was again not achieved by any of 
the bacteria at any of the repeated concentrations. 
 












Figure 9: The Effect of Starting Inoculum in 15 microliters of Blood on 
Bacteriostasis of E. coli and ESBL E. coli. 
Data shows the effect 15µL of blood has on growth of sensitive and resistant clinical 
isolate bacteria (E. coli and ESBL E. coli) at different starting inoculums compared to 
the RT5 growth controls of the bacteria in one donor after 18 hours. 
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Figure 10: The Effect of Starting Inoculum in 15 microliters of Blood on 
Bacteriostasis of S. aureus and MRSA. 
Data shows the effect 15µL of blood has on growth of sensitive and resistant clinical 
isolate bacteria (S. aureus and MRSA) at different starting inoculums compared to 
RT5 growth controls of the bacteria in one donor after 18 hours. 
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Figure 11: The Effects of Lower Starting Inoculum in 15 microliters of Blood on 
Bacteriostasis of E. coli and ESBL E. coli. 
Data shows the effect 15µL of blood has on growth of sensitive and resistant clinical 
isolate bacteria (E. coli and ESBL E. coli) at different lower starting inoculums 
compared to RT5 growth controls of the bacteria in one donor after 18 hours.  
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Figure 12: The Effects of Lower Starting Inoculum in 15 microliters of Blood on 
Bacteriostasis of S. aureus and MRSA. 
Data shows the effect 15µL of blood has on growth of sensitive and resistant clinical 
isolate bacteria (S. aureus and MRSA) at different lower starting inoculums compared 
to RT5 growth controls of the bacteria in one donor after 18 hours.  
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Figure 13: Repeat Experiment of the Effects of Lower Starting Inoculum in 15 
microliters of Blood on Bacteriostasis of E. coli and ESBL E. coli. 
Data shows the confirmed effect 15µL of blood has on growth of sensitive and 
resistant clinical isolate bacteria (E. coli and ESBL E. coli) compared to RT5 growth 
controls of the bacteria in one donor after 18 hours. 
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Figure 14: Repeat Experiment of the Effects of Lower Starting Inoculum in 15 
microliters of Blood on Bacteriostasis of S. aureus and MRSA. 
Data shows the confirmed effect 15µL of blood has on growth of sensitive and 
resistant clinical isolate bacteria (S. aureus and MRSA) compared to RT5 growth 
controls of the bacteria in one donor after 18 hours. 
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3.5 Determining Bacteriostasis Using Different Bacterial Concentrations, Fixed 
Blood Volume and Reduced Incubation Time: 
Following on from the results of the previous bacteriostasis experiment section (3.4), it 
was hypothesised that by reducing the bacterial incubation time of E. coli (5x104 
CFU/mL), ESBL E. coli (1x106 CFU/mL), S. aureus (1x104 CFU/mL) and MRSA (1x104 
CFU/mL) in the blood from 18 hours to 3 hours, bacteriostasis would be achieved 
(Figure 15). Continuing to follow section (2.13) bacteriostasis procedure, S. aureus was 
the only bacteria that achieved bacteriostasis, being inhibited by <½-log, in the two 
donor blood samples that were tested.  
Either a log increase or a 2-log increase, apart from ESBL E. coli as a 2-log increase in 
bacterial concentration is too high, of the bacterial concentrations of E. coli (5x105 and 
5x106 CFU/mL), ESBL E. coli (1x107 and 5x107 CFU/mL) and MRSA (1x105 and 1x106 
CFU/mL) was hypothesised to achieve bacteriostasis for the three bacteria. Only MRSA 
(1x106 CFU/mL) achieved bacteriostasis, being inhibited <1-log (Figure 16). After 
following the bacterial counting method in section (2.11), it was decided that due to 
previous trouble with achieving bacteriostasis for E. coli and ESBL E. coli that the 
concentrations for E. coli (5x106 CFU/mL) and ESBL E. coli (1x107 CFU/mL) would be 
used for section (2.14) experiment. 
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Figure 15: The Effects of Starting Inoculum and Reduced Incubating Time in 15 
microliters of Blood on Bacteriostasis of Clinical Isolates. 
Data shows the effect of reduced incubation time and 15 microliters of blood has on 
different mean and standard deviation concentrations of sensitive and resistant 
bacteria (E. coli, ESBL E. coli, S. aureus and MRSA) compared to RT5 controls of the 
same bacteria in two donors. (Note some standard deviation bars were cropped due to 
falling into negative values on a log scale). 
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Figure 16: The Effects of Higher Starting Inoculum and Reduced Incubating 
Time in 15 microliters of Blood on Bacteriostasis of Clinical Isolates. 
Data shows the effect of reduced incubation time and 15 microliters of blood has on 
different mean and standard deviation concentrations of the bacteria (E. coli, ESBL E. 
coli, and MRSA) compared to RT5 controls of the same bacteria in two donors. (Note 
some standard deviation bars were cropped due to falling into negative values on a 
log scale). 
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3.6 Determining the Optimum AMP and Antibiotic Combination that Inhibits 
Common Sensitive and Resistant Sepsis Causing Bacteria: 
To achieve the aim of this study, the optimum AMP and antibiotic combination that 
when compared to the antibiotic and AMP monotherapies and the Blood T3 of each 
bacteria, inhibited the bacteria in a significant manor (P-value <0.05) would be 
determined. Following section (2.14) procedure, the non-parametric one-way ANOVA 
(Friedman test) P-value (0.0013), (0.0007), (0.0009) and (0.0009) for E. coli, ESBL E. 
coli, S. aureus and MRSA respectively showed the means of each variable in the assay 
was quite significantly different from each other. All the bacteria in all three donor 
blood samples were subjected to the same conditions of blood volume, RT5 volume, 
incubation conditions and temperature.  
Only IDR-1018 alone and the Vancomycin/IDR-1018 combination compared to Blood 
T3 had significant inhibitory effects on E. coli with P-values of (0.0197) and (0.0069) 
respectively from the Dunn’s Multiple Comparisons test. However, when the two 
therapies were compared using a Mann-Whitney t-test, both with P-values of (0.0765), 
there was no significant difference between the two treatments (Figure 17).  
Only IDR-1018 alone and the combination of Vancomycin and IDR-1018 again showed 
a significant inhibition in growth of ESBL E. coli with P-values of (0.0083) and 
(0.0118) respectively from the Dunn’s Multiple Comparisons test. The Mann-Whitney 
t-test showed no significant difference between Vancomycin/IDR-1018 combination 
against either Vancomycin or IDR-1018 monotherapies with P-values of (>0.9999) for 
Vancomycin/IDR-1018 vs IDR-1018 and (0.0765) for Vancomycin/IDR-1018 vs 
Vancomycin respectively (Figure 18). This again shows that there is no significant 
difference between the combination Vancomycin/IDR-1018 and the Vancomycin and 
IDR-1018 monotherapies.  
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Unlike E. coli and ESBL E. coli, there was no significant inhibition of S. aureus by any 
of the combinations of Ceftriaxone with any of the AMPs or any of the AMP or 
antibiotic monotherapies (Figure 19). The same is true for MRSA, there was not 
significant inhibition of the MRSA from either the combination of Ceftriaxone with the 




















































































































E. coli 5x106 CFU/mL
**
*
Figure 17: The Optimum Combination of Antimicrobial Peptides (AMPs) and 
Vancomycin to Kill Clinically Isolated E. coli.  
Data shows the effect the combination/monotherapy has on the clinical isolate E. coli 
in three donors and the mean of each variable. A Friedman test (non-parametric one-
way ANOVA) with Dunn’s Multiple Comparisons test (Blood T3 against the other 
variables) and Mann-Whitney test (non-parametric t-test determining if significant 
difference exists between combination/monotherapy pairs showing significant 
bacterial growth reduction) were performed on with a 0.05 significance. A p-value of 
(0.0013) the Friedman test shows the means of all variables are significantly 
different, a p-value of (0.0197) IDR-1018 and (0.0069) Vancomycin/IDR-1018 
compared to Blood T3 showed significant difference in bacterial growth from the 
Dunn’s Multiple Comparisons test and a p-value of (0.0765) IDR-1018 vs 
Vancomycin/IDR-1018 and (0.0.0765) Vancomycin vs Vancomycin/IDR-1018 were 
not significantly different. Growth Control (GC), Vancomycin (Vanc), Scramble LL-
37 (ScLL-37) Lactoferrin (LF), Innate Defence Regulator peptide-1018 (IDR-1018), 
recombinant Bactericidal/Permeability Increasing protein 21 (rBPI21) and Versus (vs). 
(Note 100 represents 0 CFU/mL as 0 cannot be put on a logarithmic axis and the 
horizontal line represents the mean) 














































































































ESBL E. coli 1x107 CFU/mL
**
*
Figure 18: The Optimum Combination of Antimicrobial Peptides (AMPs) and 
Vancomycin to Kill Clinically Isolated ESBL E. coli.  
Data shows the effect the combination/monotherapy has on clinical isolate ESBL E. 
coli in three donors. A Friedman (non-parametric one-way ANOVA) with Dunn’s 
Multiple comparisons test (Blood T3 against the other variables) and Mann-Whitney 
test (non-parametric t-test determining if significant difference exists between 
combination/monotherapy pairs showing significant bacterial growth reduction) were 
performed with a 0.05 significance. A p-value of (0.0007) the Friedman test shows 
the means of all variables are significantly different with the following p-values of 
(0.0083) IDR-1018 and (0.0118) Vancomycin/IDR-1018 compared to Blood T3 
showed significant difference in bacterial growth from the Dunn’s Multiple 
Comparisons test and a p-value of (>0.9999) IDR-1018 vs Vancomycin/IDR-1018 
and (0.0765) Vancomycin vs Vancomycin/IDR-1018 were not significantly different. 
Growth Control (GC), Vancomycin (Vanc), Scramble LL-37 (ScLL-37) Lactoferrin 
(LF), Innate Defence Regulator peptide-1018 (IDR-1018), recombinant 
Bactericidal/Permeability Increasing protein 21 (rBPI21) and Versus (vs). (Note 10
0 
represents 0 CFU/mL as 0 cannot be put on a logarithmic axis and the horizontal line 
represents the mean). 










































































































S. aureus 1x104 CFU/mL
Figure 19: The Optimum Combination of Antimicrobial Peptides (AMPs) and 
Ceftriaxone to Kill Clinically Isolated S. aureus. 
Data shows the effect the combination/monotherapy has on the clinical isolate S. 
aureus in three donors. A Friedman (non-parametric one-way ANOVA) with Dunn’s 
Multiple comparisons test (Blood T3 against the other variables) and Mann-Whitney 
test (non-parametric t-test determining if significant difference exists between 
combination/monotherapy pairs showing significant bacterial growth reduction) were 
performed with a 0.05 significance. A p-value of (0.0009) the Friedman test shows 
the means of all variables are significantly different, there was no significant 
difference in bacterial growth of any of the variable compared to Blood T3. Growth 
Control (GC), Vancomycin (Vanc), Scramble LL-37 (ScLL-37) Lactoferrin (LF), 
Innate Defence Regulator peptide-1018 (IDR-1018), recombinant 
Bactericidal/Permeability Increasing protein 21 (rBPI21) and Versus (vs). (Note 10
0 
represents 0 CFU/mL as 0 cannot be put on a logarithmic axis and the horizontal line 
represents the mean). 
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Figure 20: The Optimum Combination of Antimicrobial Peptides (AMPs) and 
Ceftriaxone to Kill Clinically Isolated MRSA. 
Data shows the effect the combination/monotherapy has on the clinical isolates MRSA 
in three donors. A Friedman (non-parametric one-way ANOVA) with Dunn’s 
Multiple comparisons test (Blood T3 against the other variables) and Mann-Whitney 
test (non-parametric t-test determining if significant difference exists between 
combination/monotherapy pairs showing significant bacterial growth reduction) were 
performed with a 0.05 significance. A p-value of (0.0009) the Friedman test shows 
the means of all variables are significantly different, there was no significant 
difference in bacterial growth of any of the variable compared to Blood T3. Growth 
Control (GC), Vancomycin (Vanc), Scramble LL-37 (ScLL-37) Lactoferrin (LF), 
Innate Defence Regulator peptide-1018 (IDR-1018), recombinant 
Bactericidal/Permeability Increasing protein 21 (rBPI21) and Versus (vs). (Note 10
0 
represents 0 CFU/mL as 0 cannot be put on a logarithmic axis and the horizontal line 
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4 Chapter 4 Discussion: 
4.1 Discussion of Previous Research: 
The increasing prevalence of antibiotic resistance of common sepsis causing bacteria 
demands new treatments that are better able to kill these bacteria. The combination of 
AMPs and antibiotics have shown synergistic abilities to inhibit both GN and GP 
bacteria in artificial culture conditions (127-133). Despite studies showing effective 
combinations of AMPs and antibiotics can effectively kill bacteria, there are presently 
very few studies that show different combinations of AMPs and antibiotics works, in 
human whole blood against common sepsis causing bacteria. In this study, we 
investigated different combinations of AMPs and antibiotics for their ability to inhibit 
sensitive and resistant clinical isolates of sepsis causing bacteria, in an adult blood 
model. 
The three main findings of this project were as follows: 
1. IDR-1018 alone had activity against E. coli, ESBL E. coli and MRSA 
2. Vancomycin paired with IDR-1018 had a significant additive inhibitory effect 
against E. coli and, 
3. Blood on its own did not control the bacteria used in the study. 
4.1.1 AMP Monotherapy Activity Against the Bacteria Used in the Study: 
The first main finding of this study was that IDR-1018 was the only monotherapy to 
inhibit E. coli, MRSA and ESBL E. coli but not S. aureus, though only E. coli and ESBL 
E. coli were significantly inhibited. IDR-1018 inhibition of E. coli and ESBL E. coli was 
a 2.2-log reduction and a 6-log reduction respectively. While IDR-1018 has not been 
tested against ESBL E. coli studies by Wieczorek et al. (137) and de la Fuente-Núñez et 
al. (138) showed that IDR-1018 has a weak affect against GN bacteria such as 
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P. aeruginosa PAO1, E. coli 0157 and a greater effect against GP bacteria such as 
ATCC 25923 S. aureus and MRSA. Though this is potentially due to the method of 
measuring IDR-1018 antibacterial activity as Andresen et al. (139) found IDR-1018 had 
the same antibacterial activity against both biofilms and planktonic growth of P. 
aeruginosa PAO1. In our study, while IDR-1018 had a greater effect against MRSA, E. 
coli and ESBL E. coli compared to the other AMP monotherapies used in our study, it 
did not have increased inhibition against the bacteria, particularly S. aureus and E. coli 
in our study, whose IDR-1018 MIC values were lower than the 50µg/mL concentration 
used in our study (137, 138).  
The reason could be when IDR-1018 was inoculated into the blood samples there was 
variation between the bloods response to IDR-1018, or there could be variance in IDR-
1018 sensitivity between different bacterial strains combined with the physiological 
condition of our study favouring a greater effect on ESBL E. coli and MRSA than E. coli 
and S. aureus. For S. pneumoniae, a bacterium not used in our study in artificial culture 
conditions, the difference in natural AMP susceptibility between strains is genetic in 
nature, due to different serotypes and finally because of variation between transparent 
and opaque variants of the same bacteria, opaque variants having more capsular 
polysaccharides than the transparent variants (140, 141). Genetic differences between 
strains could explain the difference in IDR-1018 inhibition between ATCC 25923 S. 
aureus and the S. aureus clinical isolate in our study (137). IDR-1018 can kill 
bioluminesant S. aureus-Xen36 with or with physiological ion levels being present in 
artificial culture conditions (142). Finally, the reason IDR-1018 had greater activity 
against the bacteria in our study compared to the other AMPs could be because IDR-
1018 is a synthetic AMP and the bacteria are not resistant to IDR-1018 like they are to 
the other natural AMPs used in the study.   
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rBPI21, did not have any affect against any of the bacteria in our study, natural BPI has a 
strong effect on GN bacteria and the LPS the bacteria produce (143, 144). rBPI21 has 
been found to have a permeabilizing effect against cell wall deficient L-form GP 
bacteria, such as S. aureus, and cell membrane permeabilization of ATCC 25922 E. coli 
(complete permeabilization) and ATCC 25923 S. aureus (partial permeabilization) 
(102, 104) and varied susceptibility to rBPI21 from GN bacteria (136). The result found 
for MRSA in our study is likely due to donor variation, this is the most likely 
explanation because as stated before rBPI21 has a varied effect on GP bacteria, and 
rBPI21 so far has not been tested against MRSA, but rBPI21 has been tested against S. 
aureus (102, 104). The result observed for S. aureus, most likely is because the S. 
aureus used in our study is a clinical isolate compared to Domingues et al. (104) ATCC 
25923 S. aureus, meaning that our S. aureus strain may be more resistant to rBPI21. The 
near total resistance to natural human-BPI and rBPI23 by S. aureus (Cowan strain) has 
also been observed, showing that different strains of S. aureus have different levels of 
sensitivity or resistance to natural and rBPI (145).  
Levy (143) and Vaara (146) showed bacteria that resist Polymyxins also resist natural 
BPI by modifying the lipid A part of LPS stopping either molecule getting to their 
target. Polymyxin resistance in unlikely for why rBPI21 in our study did not inhibit E. 
coli and ESBL E. coli, as a study by Urban et al. (147) showed that A. baumannii, a 
bacteria not used in our study, was susceptible to rBPI21 despite having Polymyxin B 
resistance. A study by Weitz et al. (148) found rBPI21 had a significant inhibitory effect 
against MDR GN bacterial clinical isolates A. baumannii, P. aeruginosa and laboratory 
strain E. coli K1/r, but not MDR K. pneumoniae. Indicating some GN bacteria can resist 
rBPI21. Thus ESBL E. coli in our study may be resistant to rBPI21 in some way, as 
presently there are no studies on rBPI21 or even natural BPI against ESBL E. coli. 
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Another factor stopping rBPI21 from inhibiting E. coli and ESBL E. coli, could be the E. 
coli and ESBL E. coli inoculum size as for Weiss et al. (145) the inoculum range for E. 
coli K1/r was (1x104, 1x105 and 1x106 CFU/mL), where ours was (5x106 and 1x107 
CFU/mL) for E. coli and ESBL E. coli respectively. This study was using natural BPI, 
but this does not disprove the idea the inoculum was too large for rBPI21 to effectively 
inhibit, this could mean the AMPs killing ability, like antibiotics, is affected by the size 
of the inoculum. Natural BPI has been found to work when inoculated into blood as 
shown by Weiss et al. (145), they showed that unlike a lot of AMPs, BPI does not lose 
activity when exposed to physiological NaCl levels. When rBPI21 was inoculated in 
neonatal cord blood and adult blood in the study by Levy et al. (136), rBPI21 had an 
antimicrobial effect in blood against bacteria both sensitive and intermediate to rBPI21 
meaning that it is not inhibited blood.  
We found LF had no inhibitory effect on the bacteria in our study. This is interesting as 
there have been many studies and reviews on different versions bacterial inhibiting 
ability of LF on different bacteria including E. coli, S. aureus and MRSA though again 
ESBL E. coli has not been tested against LF of any kind Arnold et al. (149), Nibbering 
et al. (150), Chen et al. (151), Yekta et al. (152), Yen et al. (153), Drago-Serrano et al. 
(154), Yen et al. (155), Venkatesh et al. (156) and Aguila et al. (157). Like rBPI21, LF 
does not lose its antimicrobial ability when inoculated into blood as shown by 
Siqueiros-Cendón et al. (158). The reason for LF not having an effect against the 
bacteria in our study may be due to resistance to LF, as a studies by Arnold et al. (149), 
Nibbering et al. (150) and Aguila et al. (157) found that clinical isolates of E. coli were 
not inhibited by either iron saturated-LF and apolactoferrin (non-iron saturated LF). The 
non-enteropathic E. coli required 42µM of apolactoferrin to inhibit it and was not 
inhibited by the iron saturated-LF. Clinical isolates of S. aureus had variable sensitivity 
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or resistance to LF, but all the S. aureus in Aguila et al. (157) had a much higher degree 
of resistance to LF than the laboratory strains of bacteria used in their study. Iron 
saturation and general LF resistance could explain why S. aureus, MRSA, E. coli and 
ESBL E. coli were not affected by LF and should be looked at in future studies. 
LL-37, like all the other AMPs in our study, has had its activity against different GN 
bacteria and GP bacteria, including S. aureus and E. coli documented Cirioni et al. 
(159), Noore et al. (160), Guilhelmelli F et al. (161) and Turner J et al. (162), however 
studies and reviews have shown LL-37 resistance from S. aureus, MRSA, E. coli, ESBL 
E. coli (127, 163-168), meaning that the result obtained in our study could be due to 
LL-37 resistance or through strain variation in the case of S. aureus as at the 
concentrations (1.0, 0.5, 0.25 and 0.05µM) there was greater killing of clinical isolate S. 
aureus compared to ATCC 25923 S. aureus (160). When LL-37 is inoculated into 
blood, the antimicrobial activity is inhibited, and it takes on an immunomodulatory role 
instead of inhibiting the bacteria (97, 114). This could also explain what happened in 
our study, the exposure of the LL-37 to the blood plasma inhibited its activity and thus 
it did not work on the bacteria. Donor variation could explain why S. aureus was 
completely inhibited in one donor and not the other donors in our study. To make sure 
that the aa sequence of LL-37 was not producing a potential bias when acting on the 
bacteria in our study, a version of LL-37 with a scrambled aa sequence (scLL-37) was 
used as a control for LL-37 like in our study (169). The results of scLL-37 show that the 
sequence of LL-37 does not affect the antimicrobial ability on the bacteria as both scL-
37 and LL-37 were not able to inhibit the bacteria in any significant manor.  
Finally, the blood itself could have an inhibitory effect on the AMPs through proteolytic 
degradation of the AMPs, as the stability of AMPs are impaired in the presence of 
proteolytic enzymes in the blood (123). This is probably not the case for the AMPs used 
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in our study as LL-37, natural BPI and LF are resistant to proteolytic degradation from 
the donated blood sample (114, 170-172). LF in particular has a resistance to proteolytic 
degradation from trypsin and trypsin-like enzymes proportional to its iron saturation, 
and rBPI21 is shown to be a stable AMP (170, 172). IDR-1018s stability in blood has 
not be reviewed before but because it is a synthetic AMP it may have gained increased 
stability through its design.      
4.1.2 AMP and Antibiotic Combination Effect on the Bacteria Used in the Study:  
The second main finding of this study was that Vancomycin paired with IDR-1018 had 
a significant additive inhibitory affect against E. coli and ESBL E. coli, Vancomycin 
alone had no effect against E. coli or ESBL E. coli. The inhibition of E. coli the 
combination of IDR-1018 and Vancomycin achieved was a 6-log reduction of the 
bacteria, for ESBL E. coli the IDR-1018 and Vancomycin combination achieved almost 
a 6-log inhibition of ESBL E. coli. However as discussed before, for ESBL E. coli, IDR-
1018 alone had a similar significant inhibitory effect compared to the IDR-1018 and 
Vancomycin combination, due to potential variation in IDR-1018 sensitivity between E. 
coli and ESBL E. coli. The effect of Ceftriaxone and the different AMP combinations, 
against S. aureus and MRSA was different than Vancomycin and the different AMP 
combinations against E. coli and ESBL E. coli. There was no combination of 
Ceftriaxone and AMPs that had a significant killing effect on MRSA or S. aureus.  
The IDR-1018 and Vancomycin result is significant because normally Vancomycin has 
no effect against GN bacteria only GP bacteria are affected (55, 173). The synergy IDR-
1018 has with antibiotics has been shown in other studies against different bacteria, 
including E. coli and S. aureus (97, 174-176). Though Vancomycin and IDR-1018 have 
not been tested for synergy against E. coli and ESBL E. coli before, Vancomycin has 
been tested for synergy with synthetic AMPs (DP7 and CLS001) against three clinical 
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isolates of E. coli, (131). The result was that DP7 had synergistic activity, defined as a 
FIC of (≤0.5), with Vancomycin against all E. coli strains they tested it against, but the 
CLS001 AMP had additive (<0.5 FIC <1.0) or indifferent activity (≤1 FIC <4.0) with 
Vancomycin against the three clinical isolate E. coli strains.  
This combination effect between IDR-1018 and Vancomycin caused Vancomycin at a 
concentration of 20µg/mL, the highest plasma concentration that is safe for 
administration (Vancomycin: Neonatal Medication Protocols), to kill both E. coli in a 
significant manor. Both E. coli and ESBL E. coli were found to be extremely resistant to 
Vancomycin, only being inhibited at the highest concentration of 512µg/mL in section 
(3.2). As Vancomycin molecules have low permeability due to being too large to fit 
through the small porin channels of the OM GN bacteria have (55, 173), this confirms 
that through combined action the combination could overcome this resistance of E. coli. 
Thus this finding has partially validated the hypothesis of our study, the reason may be 
due to IDR-1018 being designed to have a higher immunomodulatory effect, and being 
found to have increased synergy with antibiotics (97). Thus, when IDR-1018 is 
inoculated with Vancomycin it was able to significantly kill E. coli.  
The IDR-1018 and Ceftriaxone combination showed 3-log inhibition of MRSA and 
complete inhibition of S. aureus, but neither was a significant inhibition of the bacteria. 
The observed effect of the Ceftriaxone and IDR-1018 combination, and the other AMPs 
Ceftriaxone was combined with, may have been due to the Ceftriaxone against MRSA 
and S. aureus, like IDR-1018 and Vancomycin against ESBL E. coli. So, there may 
have been no synergy observed between Ceftriaxone and IDR-1018, as the IDR-1018 
had as stated before the same level of inhibition against MRSA, meaning that the 
combination of IDR-1018 and Ceftriaxone may an antagonistic combination. The 
combination of IDR-1018 with Ceftriaxone against S. aureus or MRSA has however not 
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been tested before, so future studies will need to evaluate all the combinations used in 
our study to determine whether the combinations are indeed synergistic, additive, 
indifferent or antagonistic.  
The MRSA resistance to Ceftriaxone that was found in section (3.2) of our study is 
confirmed in the study conducted by Phe et al. (177). They however, found the MIC to 
be only 32µg/mL while section (3.2) MIC for MRSA in our study was 252µg/mL. 
Interestingly the MIC of our clinical isolate S. aureus (32µg/mL) and ATCC 25923 S. 
aureus (16µg/mL) was also higher than the MIC found for MSSA (1-8 µg/mL). 
Meaning even our sensitive S. aureus and ATCC 25923 S. aureus has resistance to 
Ceftriaxone. This shows potential variation in Ceftriaxone susceptibility between strains 
of clinical isolate S. aureus, for ATCC 25923 S. aureus the reason it was resistant to 
Ceftriaxone could be because Phe et al. (177) used ATCC 25913 S. aureus, and ATCC 
25923 S. aureus is normally used for disc diffusion MIC but can also be used for broth 
microdilution MIC (178).  
From the ATCC 25923 S. aureus MICs we observed in section (3.2) (data not shown on 
graph), it was similar to ATCC 25913 S. aureus in the CLSI M100-S25 and Eucast2 
apart from Ceftriaxone, meaning the ATCC S. aureus we used was still a viable quality 
control bacterium in our study. The Ceftriaxone concentration used though, 156µg/mL, 
was less than the MIC found for MRSA (252µg/mL) but more than the MIC found for S. 
aureus (32µg/mL). The plasmas concentration for Ceftriaxone was not shown on 
(Ceftriaxone: Neonatal Critical Care Unit Medication Protocol). Thus, the concentration 
was chosen because the average Ceftriaxone concentration for preterm and term infants 
was 156µg/mL. This concentration was determined by averaging preterm intravenous 
plasma concentration 153µg/mL with the term infant intramuscular plasma 
concentration 159µg/mL, the two values that were most similar to each other (179). 
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This meant that MRSA would not be killed by Ceftriaxone, but S. aureus would be. A 
way to be sure that Ceftriaxone alone is not the only part of the combination working on 
MRSA would be to reduce the concentration of Ceftriaxone to <32µg/mL this way there 
is no doubt Ceftriaxone will not work on MRSA and will have a reduced concentration 
for S. aureus as well. This will also mean that if the combination works on MRSA at this 
low a concentration, then it would allow for the reduction of Ceftriaxone concentration 
when treating MRSA sepsis infection.  
When rBPI21 was combined with Vancomycin the combination did show some 
inhibitory effect against ESBL E. coli, but this was not a significant and the spread of 
the data shows potential donor variation in terms of response to the combination 
treatment. A study by Cohen et al. (180) for using natural BPI, rBPI21 and rBPI23 with 
antibiotics to treat GN bacteria including E. coli, but presently there are no studies 
presently that test Vancomycin and rBPI21. Cohen et al. (180) found synergy between 
different version of BPI and multiple different antibiotics, such as Ceftriaxone and 
rBPI21 against E. coli but they did not test this against ESBL E. coli. The combination of 
rBPI21 and Ceftriaxone against clinical isolate S. aureus has been tested before by 
Horwitz et al. (181), they found that increased rBPI21 concentration lowered the MIC90, 
and thus lowered the resistance, of S. aureus for eight (Amoxicillin/K clavulanate 
(Augmentin), Cefotaxime, Ceftriaxone, Cefuroxime, Cephalothin, Chloramphenicol, 
Imipenem and Sulfamethoxazole) of the 25 antibiotics that were tested. The other 
antibiotics when combined with rBPI21 were not able to alter the susceptibility pattern 
of S. aureus. MRSA was not tested and as before there is no combination of rBPI21 and 
antibiotic that have been tested against MRSA.    
The combination of human LF and Vancomycin has not been tested before in other 
studies, the closest studies to ours are Vorland et al. (182) and Flores-Villaseñor et al. 
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(183). What was found by Vorland et al. (182), was a partial synergy of Vancomycin 
and Lactoferricin B in the killing of ATCC 25922 E. coli, meaning the combination of 
Lactoferricin B and Vancomycin had an antimicrobial effect that was equal to the sum 
of its parts. In the study by Flores-Villaseñor et al. (183), they found that against MDR 
clinical isolate Enteropathogenic E. coli, the combination of Ampicillin and either  
LFcin17-30 or LFampin265-284, there was synergistic activity that inhibited the 
bacteria by 94%. The reason our combination of Vancomycin and LF did not work 
against both E. coli and ESBL E. coli may be due to LF resistance combined with the 
Vancomycin resistance or the LF in our study had antagonism with Vancomycin. LF 
resistance may also be a reason why Ceftriaxone combined with LF did not have an 
increased inhibitory effect. There have been no studies on the combination of LF and 
Ceftriaxone against either S. aureus or MRSA but there have been similar studies that 
include different versions of LF, including human LF we used, with different antibiotics 
against S. aureus and MRSA (183-185). What was found from all these studies was that 
the different forms of LF with the different antibiotics, had either indifference or 
synergy against S. aureus and MRSA. 
The combination of LL-37 with Vancomycin or Ceftriaxone against E. coli, ESBL E. 
coli and S. aureus has not be evaluated in previous studies before, however the 
combination of LL-37 and Ceftriaxone and other β-antibiotics against MRSA has been 
evaluated by Sakoulas et al. (186). They found when Ceftriaxone and other β-lactam 
antibiotics at a concentration of 2µg/mL, except the anti-MRSA Ceftaronline at 
0.063µg/mL (25% of its MIC), were incubated with LL-37 for one hour against MRSA 
D712. All the combinations showed significant inhibition of MRSA D712 with 
Ceftriaxone, Ceftaronline and Nafcillin being the most pronounced with <50% MRSA 
D712 survival each. Sakoulas et al. (186) also found Vancomycin, Linezolid and 
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Daptomycin, non-β-lactam anti-MRSA antibiotics, when incubated with LL-37 for one 
hour at the sub-inhibitory concentrations (1.0, 0.5 and 2.0µg/mL) respectively, none of 
the antibiotics in combination with LL-37 achieved any significant inhibition of MRSA 
D712. This shows LL-37 synergises, better with certain antibiotics by lowering those 
antibiotics required MICs. Our MRSA result is similar to this, but it may be due to the 
Ceftriaxone as it alone had the same effect as the combination, indicating that 
Ceftriaxone is the part of the combination that is affecting the MRSA.  
Sakoulas et al. (187), showed that the combination of Cefazolin with LL-37 had greater 
killing than the combination of, the two β-lactam antibiotics, Ertapenem and Cefazolin 
against MSSA. But there was no synergy between Ertapenem and LL-37 and finally, the 
greatest synergy against MSSA was the combination of Ertapenem-Cefazolin and LL-
37. Strain variation between our S. aureus clinical isolate and the MSSA clinical isolate 
Sakoulas et al. (187) used, the blood inhibiting the antimicrobial activity of LL-37 and 
donor variation could be a reason why the Ceftriaxone and LL-37 combination did not 
have a significant inhibitory effect against S. aureus in our study. There is a similar 
study for LL-37 synergy with Azithromycin against MDR GN bacteria by Lin et al. 
(128), this study found that the combination of LL-37 and Azithromycin had synergistic 
activity against MDR P. aeruginosa, K. pneumoniae and MDR A. baumannii. This 
means that the reason Vancomycin and LL-37 did not work in our study could again be 
due to resistance mechanisms by both E. coli and ESBL E. coli or LL-37 does not have 
synergy with Vancomycin.  
Another reason why none of the combinations of Vancomycin or Ceftriaxone with LL-
37, LF or rBPI21, significantly inhibited the E. coli, ESBL E. coli, S. aureus or MRSA 
could be the time the bacteria were incubated with the combination treatments. In our 
study the bacteria were incubated for 3-hours at 37ºC with 5% CO2. From sections (3.3, 
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3.4 and 3.5) a 3-hour incubation, was more effective than an 18-hour incubation at 
achieving bacteriostasis in our study. This could be another reason why the 
Vancomycin and AMP combinations, other than Vancomycin and IDR-1018, did not 
work as Vancomycin is a time-dependant antibiotic like Ceftriaxone (188, 189). . Future 
studies should examine, through a time-kill curve, the inhibitory rates of the 
combination treatments and monotherapies used in our study. And if the combinations 
in our study have either a synergistic, additive, indifferent or antagonistic effect. This 
would determine, if the combination treatments are time-dependant in exerting a 
significant inhibitory effect on the bacteria in our study. And would also confirm the 
interactions of the combinations in our study. The effect Ceftriaxone, alone and in 
combination with the different AMPs, had on MRSA could be due to the 156µg/mL 
dose being a sub-inhibitory MIC (Figure 3), that partially inhibits MRSA by 3-logs but 
does not completely inhibit MRSA in some of the donors (Figure 20). Donor variation in 
response to Ceftriaxone may explain why MRSA was completely inhibited in one of the 
donors. The reason Ceftriaxone was not able to effectively kill S. aureus in some of the 
donors in our study, may be due to Ceftriaxone potentially being significantly less 
effective in serum as Bassler et al. (190) found. It was also found by Bassler et al. (190) 
that Ceftriaxone improves leukocyte bactericidal activity against P. aeruginosa in the 
absence of serum but not for S. aureus. Donor variation in Ceftriaxone response like 
MRSA could explain why one of the donors in our study was able to completely inhibit 
S. aureus.   
4.1.3 The Donor Blood Sample’s Effect on the Bacteria Used in the Study 
The third main finding of this study was that the endogenous levels of native AMPs and 
the immune cells in the donated blood did not have any effect on the bacteria used in 
our study. A study similar to ours is done by Levy et al. (136) looked at adding rBPI21 
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neonatal cord blood and adult blood against E. coli K1/r, and clinical isolates of 
Citrobacter koseri, Enterobacter agglomerans, E. cloacae, K. pneumoniae and Serratia 
marcescens. They found that adult blood was able to limit the growth of all the bacteria 
apart from K. pneumoniae while cord blood provided an uninhibited growth medium for 
the bacteria. The results of our study were similar, as we were modelling preterm infant 
sepsis the blood.  
The results of section (3.3, 3.4 and 3.5) show E. coli and ESBL E. coli grew after 3-hour 
incubation in all three donors but S. aureus was inhibited slightly, and MRSA was 
unchanged in terms of growth. E. coli and ESBL E. coli were particularly challenging to 
achieve bacteriostasis for, as discussed before the study by Weiss et al. (145) confirmed 
that the concentrations chosen for both E. coli (5x106 CFU/mL) and ESBL E. coli 
(1x107 CFU/mL) respectively were correct as the blood killed any concentration below 
these concentrations and was within the range of killing by Weiss et al. (145), though 
both their clinical blood isolate of E. coli (K1/r and J5) were either partially or 
completely inhibited respectively up to a concentration of 1x107 CFU/mL, again this 
could just be variation between the donor blood samples and the isolates of E. coli 
between their study and our study.  
These results were repeated in section (3.6) were the bacteria grew virtually the same 
way as they did in sections (3.3, 3.4 and 3.5), by doing this the factor of blood being 
responsible for killing the bacteria was able to be minimised and the killing ability of 
the combination could be seen more clearly. A way to be sure that the endogenous 
AMPs in the blood are not sufficient alone to kill the bacteria, is to deplete the blood of 
all the endogenous AMPs. This way there is no potential additive affect from 
endogenous AMPs in the blood and the killing effect of the monotherapies and the 
combination therapies can be measured.   
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4.2 Conclusion: 
To summarise, the study evaluated the antimicrobial effect of different combinations of 
AMPs and antibiotics against sensitive and resistant clinical isolates of common 
neonatal sepsis causing bacteria. We found was that IDR-1018 was the only 
monotherapy AMP that had any activity against the bacteria in the study. The bacteria 
in this study may not have resistance to synthetic peptide like IDR-1018. The 
differences in inhibition patterns found in the study may also be due to strain variation 
in the terms of the sensitivity between the bacterial clinical isolates used in the study. 
This shows that IDR-1018 has more activity against the clinical isolates of bacteria used 
in this study. Thus IDR-1018 can be used as a monotherapy to treat bacterial sepsis, but 
it will require further assessment of the sepsis causing bacteria’s sensitivity to IDR-
1018. As the bacterial species may not be sensitive to IDR-1018 like ESBL E. coli was 
in this study, as well as this the patient should be tested for response to IDR-1018 to see 
if they will positively respond or will only be partially affected. 
When IDR-1018 was used in combination with the antibiotic Vancomycin, it had a 
significant inhibitory affect against the sensitive clinical isolate E. coli. This is a 
significant result as it means that when IDR-1018 is used in combination with 
Vancomycin, the peptide can help overcome the innate resistance of GN bacteria to 
Vancomycin. This could allow patients affected by E. coli sepsis, to be treated using the 
combination found in this study and extend the available antibiotics for GN infections. 
The synergy between IDR-1018 and Vancomycin most is likely either due to the two 
treatments working in series, meaning that IDR-1018 may be translocating into E. coli 
and perturbing cell wall synthesis causing E. coli to start to lyse (137). Allowing 
Vancomycin to move in and kill E. coli through inhibition of the second stage of cell 
wall synthesis (55, 68). Or working in parallel, by targeting different sites of the same 
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target such as Vancomycin again targeting the phosphatidylglycerol of the cell 
membrane and IDR-1018 targeting a different mechanism responsible for cell wall 
synthesis (55, 68, 137).  
The effect IDR-1018 has with Vancomycin seems to also be strain specific as when 
IDR-1018 was used by itself and with Vancomycin against ESBL E. coli, the observed 
effect between the two treatments was the same. On the other hand, the combination of 
Ceftriaxone with different AMPs did not have any combination that was able to 
significantly inhibit any of the bacteria in the study, this is likely due to the different 
responses of Ceftriaxone between the donors and because of the concentration 
Ceftriaxone was inoculated into the blood samples.  
Finally, the last finding of this study was that the endogenous AMPs and immune cells 
present in the blood samples did not have any effect on the bacteria that was inoculated 
into the samples. The bacteria either grew, are slightly inhibited or did not change at all 
in terms of bacterial growth. This means that there is need for a new treatment as the 
antibiotics alone in this study also did not have a significant if any effect against the 
bacteria used in this study. 
Future studies should examine what the lowest possible Vancomycin dose when paired 
with IDR-1018 that can still inhibit E. coli, if the concentration of the Vancomycin can 
be lowered past 10µg/mL, the lowest concentration of Vancomycin used to kill the 
bacteria, this can improve Vancomycin administration as 20µg/mL is highest dose that 
is safe for neonates. The same should be done for Ceftriaxone as again the mean 
concentration for neonates is 156µg/mL. if this concentration can also be lowered like 
Vancomycin while still killing bacteria with AMPs being used to assist this killing then 
this will again mean that the concentration of Ceftriaxone can be lower thus enabling 
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less antibiotic being required to kill the bacteria thus reducing the burden on the 
neonate, in terms of also reducing the side effects and decrease the chance of resistance 
developing (125). The combination of IDR-1018 and Vancomycin also shows if there is 
synergy between AMPs and antibiotics, not only can it revive antibiotic effect but also 
create sensitivity to antibiotics that were never there before. 
This study overall, has offered valuable information in terms of antimicrobial ability 
and the potential interactions of AMPs and Antibiotics together in vitro against sensitive 
and resistant clinical isolates of sepsis causing bacteria (E. coli, ESBL E. coli, S. aureus 
and MRSA) compared to AMPs and Antibiotics alone when inoculated into healthy 
human blood samples.  
4.3 Limitations: 
The limitations of our study are as follows: 
1. The small, three donor, sample size for section (2.14) experiment in our study. 
2. The varying sensitivity of the bacteria to the antibiotics, particularly the 
sensitive and resistant S. epidermidis both being sensitive to Vancomycin 
necessitating its removal from the study thus lowering the number of bacteria 
being tested from six to four in section (3.2). 
3. Human error in conducting the Piperacillin-Tazobactam MIC section (2.12) 
causing the Tazobactam concentration to not be fixed and ultimately cause 
variance in the E. coli, ESBL E. coli, S. aureus and MRSA MICs section (3.2) 
4. The number of antibiotics being decreased from four to two due to section (3.2) 
showing ESBL E. coli was resistant to three of the four antibiotics were as 
MRSA was only resistant to one of the four, meaning that to have equal testing 
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for all the bacteria in the study one antibiotic was chosen for each sensitive and 
resistant group.  
5. The variation of the donated blood samples response to bacterial inoculation. 
6. The 3-hour incubation time of the bacteria in the blood to remove blood killing 
as a factor being shorter than the 18 to 24-hours required for the AMP/antibiotic 
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